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Abstract 
Ruthenium(II)-arene RAPTA-type compounds have been extensively explored for 
their medicinal properties. Herein a comprehensive review of this class of compounds 
is provided. A discussion of the basic RAPTA structure is given together with the ways 
it has been modified to elucidate the key role of each part and to afford targeted 
derivatives. The various mechanistic studies conducted on RAPTA compounds are 
described and these are linked to the observed macroscopic biological properties. 
Ultimately, the review shows that certain RAPTA compounds display quite unique 
properties that point towards a clinical investigation. 
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Abbreviations 
[9]aneS3, 1,4,7-trithiacyclononane ligand; acac, acetylacetone; apo-Tf, apo-
transferrin; BCN, bicyclo[6.1.0]non-4-yn-9-ylmethanol; BRCA1, human breast cancer 
suppressor gene 1;  CAM, chicken chorioallantoic membrane; carbo-RAPTA, [Ru(η6-
p-cymene)(C6H6O4)(PTA)]; CEMA, 2-chloroethyl methacrylate; CORM, carbon 
monoxide releasing molecule; CP, conjugated peptide; ct-DNA, calf thymus DNA; 
CZE, capillary zone electrophoresis; cod, 1,5-cyclooctadiene; cyt, cytochrome-c; 
DAPTA, 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane; DFT, density 
functional theory; dGMP, 2’-deoxyguanosine 5’-monophosphate; DLS, dynamic light 
scattering; DNA, 2’-deoxynucleic acid; donq, 5,8-dioxido-1,4-naphthoquinonato; en, 
ethylenediamine; ESI-MS, electrospray ionization mass spectrometry; EtG, 9-
ethylguanine; EPR, enhanced permeability and retention; FDA, Food and Drug 
Administration; GSH, glutathione; GST, glutathione S-transferase; hmb, 
hexamethylbenzene; hA3AR, human A3 adenosine receptor; HSA, human serum 
albumin; IC50, half maximal inhibitory concentration; ICP, inductively coupled plasma; 
KP1019, indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]; LA-ICP-MS, 
laser ablation inductively coupled mass spectrometry; log POW, octanol-water partition 
coefficient; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; 
mPTA, N-methyl-1,3,5-triaza-7-phosphaadamantane; MS, mass spectrometry; 
mTPPMS, (m-sulfonatophenyl)diphenylphosphine; MudPIT, multidimensional protein 
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identification technology; NAMI-A, imidazolium trans-[tetrachlorido(1H-imidazole)(S-
dimethyl sulfoxide)ruthenate(III)]; NCP, nucleosome core particle; nESI-FT-ICR, 
nanoelectrospray ionization Fourier transform ion cyclotron resonance; NKP1339, 
sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]; NMR, nuclear magnetic 
resonance; OTf, trifluoromethanesulfonate; oxali-RAPTA, [Ru(η6-p-
cymene)(C2O4)(PTA)]; PARPs, poly(adenosine diphosphate (ADP)-ribose) 
polymerases; pHEA, poly(2-hydroxyethyl acrylate); P(HPMA-CEMA), N-(2-
hydroxypropyl)methacrylamide/2-chloroethyl methacrylate; PLA, polylactide; PTA, 
1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane; PTN, 3,7-dimethyl-7-phospha-1,3,5-
triazabicyclo[3.3.1]nonane; QM/MM, quantum mechanics/molecular mechanics; 
RAED, [Ru(η6-arene)(en)Cl]+; RAFT, reversible addition-fragmentation chain-transfer;  
RAPTA, [Ru(η6-arene)(PTA)X2]; RAPTA-B, [Ru(η6-benzene)Cl2(PTA)]; RAPTA-C, 
[Ru(η6-p-cymene)Cl2(PTA)]; RAPTA-Im, [Ru(η6-1,2-dimethyl-3-(4-methylphenethyl)-
1H-3λ4-imidazole)Cl2(PTA)][BF4]; RAPTA-T, [Ru(η6-toluene)Cl2(PTA)]; rHSA, 
recombinant human serum albumin; scDNA, supercoiled DNA; ssDNA, single-
stranded DNA; tpt = 2,4,6-tri-(pyridin-4-yl)-1,3,5-triazine; ub, ubiquitin; VEGFR, 
vascular endothelial growth factor receptor; 
 
1. Introduction 
Platinum-based drugs comprise some of the most important chemotherapeutics in 
cancer treatments. The prototype, cisplatin, was approved by the FDA in 1978 and is 
now widely used to treat testicular, bladder and ovarian cancers [1]. Despite the 
success of cisplatin in the clinic it is not without serious problems, including severe 
side-effects such as nephrotoxicity, ototoxicity and neurotoxicity and problems 
associated with intrinsic or acquired tumor resistance [2].   
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Efforts to circumvent/mitigate these toxicity and resistance issues led to the 
development of several approved cisplatin analogues, including carboplatin and 
oxaliplatin, that exhibit lower toxicity and a wider spectrum of activity compared to 
cisplatin. A macromolecular formulation of cisplatin, termed lipoplatin, that appears to 
selectively accumulate in the tumor environment [3] is also progressing through clinical 
trials and could lead to more selective treatments with reduced side-effects [4]. Many 
other types of macromolecular systems are also under development [5]. However, 
there is still room for further improvements and an increased understanding of the 
mechanism of action of cisplatin, including resistance mechanisms, continues to spur 
research in this field [6]. 
The search for more efficacious and less toxic anticancer drugs has also embraced 
non-platinum compounds. Among many other metals, the ruthenium-based anticancer 
agents show considerable promise [7, 8]. The two lead ruthenium compounds are 
NAMI-A (imidazolium trans-[tetrachlorido(1H-imidazole)(S-dimethyl 
sulfoxide)ruthenate(III)]) and KP1019 (indazolium trans-[tetrachloridobis(1H-
indazole)ruthenate(III)]) (also studied as its more water soluble sodium salt NKP1339), 
which have been evaluated in clinical trials. NAMI-A is active against solid metastatic 
tumors and shows a remarkable degree of selectivity [9]. A phase I clinical study 
performed with NAMI-A reported disease stabilization in a non-small cell lung 
carcinoma patient but also revealed dose-limiting toxicity in the form of blistering [10]. 
A phase I/II trial combining NAMI-A with gemcitabine for the treatment of non-small 
cell lung cancer was recently undertaken with the results showing that the combination 
is less active than gemcitabine treatment alone [11]. However, at low NAMI-A doses 
the combination treatment appears to be very promising, which conflicts with usual 
clinical practices to administer the maximum tolerated doses. In contrast to the 
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selective antimetastatic activity of NAMI-A, the structurally similar trans-
[tetrachloridobis(1H-indazole)ruthenate(III)] complex exhibits particularly good activity 
in preclinical studies on the autochthonous colorectal tumor model of the rat in the 
absence of severe side effects. Phase I clinical studies with KP1019 and NKP1339 
revealed promising anticancer activity accompanied by only modest side-effects [12, 
13]. Despite the differences in their antitumor activities a common feature of these 
Ru(III) coordination compounds is believed to be that they are activated by reduction 
to more active Ru(II) species in the low oxygen environment of solid tumors. 
Additionally, there is also evidence to suggest that these compounds may be 
(selectively) delivered to tumors by protein-mediated pathways [14, 15]. 
More recently, the development of organometallic ruthenium(II)-arene compounds, 
stabilized in the +2 oxidation state by the η6-coordinated arene ligand, have introduced 
a completely different metallodrug scaffold to that of the coordination compounds that 
have entered clinical studies. Of these ruthenium(II)-arene compounds two sub-
families of compounds have been studied in detail; the RAPTA family ([Ru(η6-
arene)(PTA)X2], PTA = 1,3,5-triaza-7-phosphaadamantane; Figure 1), which are the 
focus of this review, and the [Ru(η6-arene)(en)Cl]+ (en = ethylenediamine, RAED) 
family of compounds (Figure 1) [16]. The RAED series of compounds, which were first 
reported in 2001 [17], are able to coordinate to DNA through the N7 of guanine 
residues and, when bearing an extended arene ligand such as biphenyl, 
dihydroanthracene, and tetrahydroanthracene, may concomitantly intercalate DNA. 
These compounds are cytotoxic to a range of cancer cell lines [16], including cisplatin-
resistant strains, and an in vivo study [18] established that [Ru(η6-biphenyl)(en)Cl]+ 
possesses activity against the MCa mammary carcinoma, reducing both the growth of 
the primary tumor and the development and growth of lung metastases.   
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Figure 1. Generic structures of RAPTA and RAED anticancer agents. 
 
In addition, a myriad of structurally related organometallic Ru(II) compounds have 
been prepared and their cytotoxicity to cancer cells examined [19-24].  The wealth of 
organometallic ruthenium structures devised to date has been surveyed in several 
excellent reviews where further insights into this field may be found [24-28]. 
 
This review focuses on compounds featuring the RAPTA core structure that have been 
evaluated for biological activity relevant to antitumor activity. The development of the 
prototypical RAPTA structure (Figure 1) is reviewed, charting the modulation of the 
individual structural elements  (examples are shown in Figure 2) and relating these 
changes to biological activity, through to the development of more complex RAPTA 
compounds bearing biologically active ligands and those conjugated to 
macromolecular carriers. Closely related RAPTA-type compounds are also described 
including the rapidly evolving ruthenium cyclopentadienyl family of complexes and 
compounds bearing other face-capping groups and phosphine ligands derived from 
PTA. In addition, the wealth of bioanalytical, biochemical and biophysical studies 
performed to uncover and explain the biological activities of the RAPTA compounds 
are discussed together with all the pre-clinical data currently available.  
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Figure 2. Examples of some early RAPTA compounds [29, 30]. 
 
2. The basic RAPTA structure: prototypical RAPTA compounds 
The RAPTA compounds are characterized by their piano-stool structure (Figure 1) 
where three of the ruthenium coordination sites are occupied by a η6-coordinated 
arene ligand which serves to stabilize the Ru(II) oxidation state. A further coordination 
site is occupied by the amphiphilic PTA ligand to leave two remaining coordination 
sites that are usually occupied by relatively labile chlorido ligands. The monodentate 
PTA ligand may be seen as the distinguishing feature of the RAPTA structure that 
differentiates this family of complexes from other ruthenium(II)-arene complexes 
evaluated for their anticancer activity. PTA is a sterically undemanding ligand relative 
to other phosphines (cone angle of 103°) [31] and may confer a degree of water 
solubility to the RAPTA complexes depending on the nature of the co-ligands. 
The first RAPTA structure to be reported was [Ru(η6-p-cymene)Cl2(PTA)] (1) [29], later 
abbreviated to RAPTA-C (Figure 2). This early report hinted at the potentially 
interesting biological activity of RAPTA-C in that when it was incubated with 
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supercoiled pBR322 DNA, pH-dependent DNA damage was observed. DNA damage 
was observed at pH 7.0 and below but not at physiological pH (pH ≥ 7.5), indicating 
the potential of using RAPTA-C to damage DNA selectively in diseased hypoxic cells 
(which have a reduced pH). 
The antibiotic and antiviral properties of RAPTA-C and three close analogues, [Ru(η6-
p-cymene)X2(PTA)] (X = Cl, Br, I, NCS), were evaluated shortly after the initial report 
of the DNA damaging properties of RAPTA-C [32]. Although none of the RAPTA 
compounds possessed antiviral activity, a degree of antibiotic activity was observed. 
The level of activity against a particular microbe was observed to be related to the 
nature of the leaving group (X) ligand. The in vitro DNA-damaging ability of a particular 
RAPTA complex did not correlate with the observed antimicrobial activity, suggesting 
a non-DNA-based mechanism of cytotoxicity. A study of RAPTA-C incubated with E. 
Coli, followed by the extraction and separation of intracellular proteins, that were then 
examined by laser ablation inductively coupled mass spectrometry (LA-ICP-MS), 
indicated the formation of specific protein-ruthenium interactions, implying protein-
binding may be a major factor in the activity of these compounds. 
 
Figure 3. Aquation of the prototypical RAPTA structure (e.g. RAPTA-B (2)/RAPTA-C (1)) at 
physiological pH.  The first step is the displacement of a chlorido ligand by an aqua ligand to 
yield the mono-aquated product which dominates at physiological pH (middle); further ligand 
exchange leads to a minor quantity of [Ru(η6-arene)(OH)(H2O)(PTA)]+. 
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A later study reported the in vitro anticancer activity of several new RAPTA structures 
[30]. Simple variations of the arene ligand and the use of Me-PTA in place of the PTA 
ligand were used to expand the structural diversity of the RAPTA skeleton. In the same 
study the hydrolysis profile was explored, with RAPTA-C shown to undergo rapid 
hydrolysis in aqueous solution containing 4 mM NaCl [30], whereas at a NaCl 
concentration of 100 mM, i.e. that present in blood, hydrolysis is suppressed. More in-
depth studies on the hydrolysis of RAPTA-C [33, 34] and RAPTA-B ([Ru(η6-
benzene)Cl2(PTA)] (2); Figure 2) [35] revealed that under physiological conditions of 
low chloride concentration (5 mM) the most abundant species in solution is the 
monoaquated form of the RAPTA complex, [Ru(η6-arene)Cl(H2O)(PTA)]+, with lesser 
amounts of [Ru(η6-arene)(OH)(H2O)(PTA)]+ and [Ru(η6-arene)Cl2(PTA)] also present 
with equilibrium reached within 20 min (1 mM RAPTA-C, 298 K, 150 mM NaClO4, pH 
7.8 at τ = 0; Figure 3). Hence, it may be assumed that in vivo the RAPTA compounds, 
like cisplatin, are likely to be activated to the more reactive aqua form only in a low 
chloride environment, such as that found in an intracellular environment. It would 
therefore appear that RAPTA-C is transported in the less active chlorido form in blood 
plasma and can be considered as a prodrug. Note that the pKa values of the PTA 
ligand of several RAPTA compounds, in 0.1 M NaCl solution (used to preserve the 
dichlorido form), were in the range 2.99–3.31 [30], implying that the PTA ligand is 
unlikely to be protonated under physiological conditions in vivo.  These pKa values are 
likely to be modulated as the complexes are aquated on dissolution in aqueous media.  
 
3. Anticancer Activity of RAPTA compounds 
3.1. Activity in cell lines and in in vivo models 
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The in vitro anticancer activity of the RAPTA compounds was initially evaluated 
against the TS/A adenocarcinoma and HBL-100 epithelial (non-cancerous) cell lines 
using the MTT assay (72 h exposure). Compounds possessing a PTA ligand exhibited 
no cytotoxicity towards the non-tumorigenic HBL-100 cell line (IC50 >300 μM) and only 
mild or no cytotoxicity towards the TS/A cell line (66 to >300 μM) [30]. Two compounds, 
RAPTA-T ([Ru(η6-toluene)Cl2(PTA)]) (3) and RAPTA-Im ([Ru(η6-1,2-dimethyl-3-(4-
methylphenethyl)-1H-3λ4-imidazole)Cl2(PTA)][BF4]) (4) (Figure 2), exhibited good 
cytotoxic selectivity towards the TS/A cell line over the HBL-100 cell line (74 and 66 
μM versus >300 μM, respectively). In contrast, the Me-PTA-containing compounds (5, 
6) were more cytotoxic towards the HBL-100 cell line than the TS/A cell line. An in vivo 
study of RAPTA-B and RAPTA-C was performed in mice bearing the MCa mammary 
carcinoma [30]. Neither compound was active against the primary tumors, but both 
were effective in reducing the number and weight of solid lung metastases that 
originate from the primary tumor. These promising in vivo results established RAPTA 
compounds as potential antimetastatic agents.   
 
3.2. Antimetastatic activity 
Since RAPTA-T (3) showed the highest selectivity with respect to cytotoxicity towards 
cancerous cell lines over normal cell lines a detailed evaluation of the antimetastatic 
activity of RAPTA-T in a series of in vitro and in vivo experiments was undertaken. 
Non-cancerous HBL-100, non-invasive MCF-7 human breast cancer and highly 
invasive MDA-MB-231 breast cancer cell lines were used in a series of in vitro 
experiments simulating aspects of metastatic progression, namely detachment, 
motility, invasion and adhesion experiments [36]. It was found that following treatment 
with RAPTA-T the MDA-MB-231 cell line was more resistant to detachment from 
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fibronectin or collagen IV substrates whilst remaining relatively unaffected on a poly-
L-lysine substrate relative to control cells. No effect was seen with the MCF-7 and 
HBL-100 cell lines (Figure 4) [36].  
 
 
 
Figure 4. Effect of RAPTA-T on resistance to detachment. HBL-100, MCF-7 and MDA-MB-
231 cells showing that the compound is selectively active against the highly invasive MDA-
MB-231 cell line. Adapted from ref. [36]. 
 
The ability of the MDA-MB-231 cell line to adhere to various extra cellular matrix 
components following treatment with RAPTA-T was also reduced. In contrast, the 
ability of the HBL-100 cell line to adhere to the various substrates was unaffected by 
treatment with RAPTA-T and the MCF-7 cells showed a reduced tendency to adhere 
to collagen IV and matrigel, but this effect was less than that observed with the MDA-
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MB-231 cell line. In addition, treatment with RAPTA-T reduced the ability of MDA-MB-
231 cells to migrate (~50% relative to control cells). Reduced migration was also 
observed with the MCF-7 cell line but was unchanged with the HBL-100 cell line. In 
vivo experiments comprising RAPTA-T treatment (80 mg kg-1 per day on days 8, 9 and 
12 following tumor implant) of a CBA mouse model bearing murine mammary 
carcinoma led to a negligible reduction in primary tumor growth but led to a 35% 
reduction in the weight of lung metastases, notably with a reduction in the number of 
metastases of large dimensions [36].  
Overall, RAPTA-T exerts a degree of selectivity to invasive cancer cells and metastatic 
tumors. It was suggested that treatment with RAPTA-T leads to the cell body becoming 
more rigid through changes to the cytoskeleton, which leads to the cell losing the 
flexibility required for detachment and reattachment processes. The selective 
antimetastatic activity in vivo could be rationalized from the in vitro effects and points 
towards the biological activity of the RAPTA compounds being due, at least in part, to 
their action on cell surface molecules. 
A later study [37] evaluated the effect of RAPTA-C on primary tumor growth in 
preclinical models using different dosing protocols compared to those in previous 
studies. When evaluated against human A2780 ovarian carcinoma transplanted onto 
the chicken chorioallantoic membrane (CAM) model, RAPTA-C was found to inhibit 
tumor growth by approx. 75% at a dose of 0.2 mg kg-1 per day for 5 days (starting 4 
days after tumor inoculation of the CAM). Examination of tissue sections from the 
treated tumor revealed large areas of non-proliferating tumor cells and a significantly 
reduced microvessel density in treated tissue compared to the well-vascularized viable 
tumor tissue found in controls. RAPTA-C was also evaluated in athymic mice bearing 
a LS174T colorectal adenocarcinoma on the right flank. In mice treated with RAPTA-
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C at 100 mg kg-1 per day for 11 days tumor growth was inhibited by 50% relative to 
controls whilst doses of 10 and 40 mg kg-1 per day did not lead to tumor growth 
inhibition. Analysis of the treated tumor tissue revealed a strong anti-angiogenic 
activity of RAPTA-C exemplified by a decrease in microvessel density (Figure 5), 
consistent with related earlier studies which described the antiangiogenic activity of 
RAPTA-C and RAPTA-T in a series of cell-based assays and in the CAM model [38].  
 
 
Figure 5. Immunohistochemical sections of tumors taken from RAPTA-C treated athymic mice 
with human LS174T colorectal carcinoma; (top) images of CD31 positive 
immunohistochemical sections and (bottom) images of SMA and CD31 positive 
immunohistochemical sections, both indicative of fewer mature blood vessels in the RAPTA-
C treated tumors. Adapted from ref. [37] – with permission of The Royal Society of Chemistry 
© 2014. 
 
No toxicity was associated with RAPTA-C treatment in the mouse model, even at the 
highest doses, and a biodistribution study of ruthenium 2 hours post-treatment 
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revealed fast renal excretion of ruthenium with no significant accumulation in vital 
organs. In contrast to earlier in vivo studies with RAPTA-C, this work indicates that 
with appropriate dosing protocols RAPTA-C can be extremely effective in reducing the 
volume of primary tumors – an effect that may be partly explained by the anti-
angiogenic effects demonstrated by the complex – whilst remaining essentially non-
toxic.   
The most promising in vivo data for RAPTA-C has been obtained in combination 
studies with other approved and developmental drugs. A high throughput screening 
approach commencing with nine angiostatic drugs, including RAPTA-C, was used to 
determine optimal low-dose drug combinations [39]. The optimal synergistic drug 
combination found comprises erlotinib (an endothelial growth factor receptor inhibitor 
[40]), BEZ-235 (a dual PI3K/mTOR inhibitor [41]) and RAPTA-C. This drug 
combination showed enhanced endothelial cell specificity and synergistically inhibited 
proliferation of endothelial cells. The drug combination was evaluated in two in 
vivo tumor models (A2780 tumor grown in the CAM and LS174T tumor growth in 
athymic mice) and was found to inhibit tumor growth synergistically using drug doses 
that were reduced by up to 11-fold compared to optimal single drug concentrations. 
Indeed, the single drug monotherapies displayed, at best, negligible activity in the 
animal models. In the mouse model, when used in combination with erlotinib and BEZ-
235, a single dose of RAPTA-C at 40 mg/kg was sufficient to afford a ca. 80% 
reduction in tumor growth. In the absence of RAPTA-C no effective drug combination 
could be found from the starting drugs used in the study. 
In a different type of combination therapy, RAPTA-C was used following treatment with 
axitinib, a VEGFR targeting tyrosine kinase inhibitor [42]. The role of axitinib is to 
induce a transient period of increased tumor oxygenation which simultaneously 
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reduces vascular permeability, reducing interstitial fluid pressure in the tumor and 
improving uptake of small molecule drugs. It was found that when doxorubicin, a 
nanomolar cytotoxic drug [43], was applied during the period of increased tumor 
oxygenation (known as the normalization window), its efficacy improved (A2780 tumor 
grown in the CAM). However, the improvement was small compared to that of RAPTA-
C applied during the normalization window. In the in vivo model doxorubicin applied at 
a dose of 3 mg/kg led to a reduction in tumor growth of 78%, whereas RAPTA-C, which 
is essentially not cytotoxic, led to almost 90% inhibition in tumor growth at a dose of 
only 400 g/kg (both applied after pretreatment with axitinib during tumor 
normalization). This study shows that under the right conditions extremely low doses 
of RAPTA-C can be applied in vivo without the observation of any side-effects (note 
that RAPTA-C is well tolerated at 100 mg/kg).  
 
4. Structure-activity relationships 
The promising antitumor activity and low general toxicity displayed by some of the 
original RAPTA structures, in particular RAPTA-B (2), RAPTA-C (1) and RAPTA-T (3) 
(Figure 2), prompted further investigations on the effect of modulating individual 
structural elements of the RAPTA scaffold to ascertain structure-activity relationships 
in order to obtain more efficacious compounds. This work in turn led to the 
development of more complex RAPTA structures including dinuclear analogues and 
macromolecular RAPTA conjugates. In addition, the relatively uncommon 
antimetastatic activity observed led to detailed analytical studies of their interactions 
with potential biomolecular targets, and studies on their cellular uptake and 
localization, in order to unravel their molecular mechanisms of action.  
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4.1 Systematic modulation and development of the RAPTA structure 
The η6-bound arene ligand of the piano-stool RAPTA structure may be readily 
modulated and it has been extensively varied and derivatized to introduce more 
complex functionality. The introduction of hydrogen-bonding substituents to the arene 
ligand of the RAPTA structure was investigated as a route by which hydrogen-bonding 
interactions with potential biomolecular targets could be increased alongside metal 
coordination [44]. A range of complexes were developed utilizing η6-arene ligands 
incorporating alcohol and amine functionalities, including amines able to form 
intermolecular tethers through coordination to the ruthenium center, and in some 
cases the PTA analogue, DAPTA (3,7-diacetyl-1,3,7-triaza-5-
phosphabicyclo[3.3.1]nonane), was employed in place of the PTA ligand (see 
complexes 11 and 16, Figure 6). In each case the functionalized complexes were less 
cytotoxic towards the TS/A cell line relative to the unfunctionalized analogues RAPTA-
C, RAPTA-B and RAPTA-T, and essentially non-cytotoxic towards the HBL-100 cell 
line (IC50 >600 μM in each case). In addition, for compounds with increased hydrogen-
bonding functionality lower ruthenium uptake into TS/A cells relative to RAPTA-C, 
RAPTA-B and RAPTA-T was observed after 24 h treatment – most likely explaining 
the decrease in cytotoxicity for these compounds. Interestingly, in oligonucleotide 
binding studies monitored by ESI-MS, apart from the arene-substituted RAPTA 
derivatives bearing primary amine ligands and the intramolecularly chelated 
derivative, these complexes exhibited increased reactivity towards a 14-mer 
oligonucleotide sequence relative to RAPTA-C and RAPTA-T, principally forming 
adducts through loss of the arene ligand. The lack of correlation between the reactivity 
of the complexes with the oligonucleotide and their IC50 values aligns with the 
observation of their reduced cellular uptake.   
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Figure 6. Structures of RAPTA derivatives with functionalized arene ligands and the general 
RAPTN structure (bottom right) [44, 45].  
 
A related study examined a series of RAPTA analogues with a chelating PTN (3,7-
dimethyl-7-phospha-1,3,5-triazabicyclo[3.3.1]nonane) ligand in place of the PTA 
ligand to yield complexes of the general formula [Ru(η6-arene)Cl(PTN)]X (arene = p-
cymene, benzene, toluene, hexamethylbenzene; X = Cl-, BF4-; Figure 6 – structure 18, 
bottom right) [45]. These complexes, containing a P,N chelate courtesy of the PTN 
ligand, were highly water soluble (with the sole exception of the p-cymene analogue). 
These complexes were less reactive than their [Ru(η6-arene)Cl2(PTA)] analogues in 
water. The p-cymene/benzene PTN complexes showed no evidence of ligand 
exchange in H2O over 7 days whilst the toluene analogue appeared to undergo 
aquation over 24 h with <5% of free arene observed at 72 h. The hexamethylbenzene 
analogue decomposed completely in H2O over 72 h as evidenced by loss of the arene 
ligand. It was observed that upon reaction with ubiquitin the p-cymene PTN complex 
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and RAPTA-C formed identical adducts after 72 h incubation although adduct 
formation was observed to be faster with the PTN complex. The [Ru(η6-p-
cymene)Cl(PTN)]+ complex was unreactive towards guanosine 5’-monophosphate 
over 72 h and was found only to react with a single-stranded 14-mer oligonucleotide 
when present in a 5-fold excess (ca. 10% relative intensity of adducts in nESI-FT-ICR 
mass spectra at 24 h). The cytotoxicity of the complexes against the A2780 cell line 
was assessed, with modest IC50 values of 154-278 μM observed and the toluene 
analogue being the most cytotoxic. All these complexes were more cytotoxic than 
RAPTA-C against A2780 cells. The reactivity of the complex may be mediated through 
ring-opening of the P,N chelate, in particular in the [Ru(η6-p-
cymene/benzene)Cl(PTN)]+ complexes, where aquation is not observed.  
Computational studies predicted the introduction of electron-withdrawing substituents 
to arene ligands of the RAPTA structure would modulate the equilibrium between the 
hydroxido- and aqua forms of the mono-hydrolyzed complexes at physiologically 
relevant pH [35]. The introduction of fluoroarene ligands was predicted to lower the 
pKa sufficiently that pH differences between healthy tissue and cancerous tissue could 
be exploited. In the more acidic cancer tissue, the more active aqua-form of fluoro-
RAPTA would dominate whereas in healthy cells the more inert hydroxo-form should 
dominate, thus enhancing selectivity. Three RAPTA complexes, [Ru(η6-
fluoroarene)Cl2(PTA)] (fluoroarene = C6H5F (19), C6H5CF3 (20) and 1,4-C6H4CH3F 
(21); Figure 7), were prepared to evaluate this hypothesis and were accessed through 
an atypical route involving fluoroarene exchange with a [Ru0(η6-napthalene)(η4-cod)] 
intermediate due to safety issues associated with Birch reductions of halogenated 
arenes [46]. 
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Figure 7. Structures of fluoro-RAPTA derivatives [46]. 
 
In aqueous solution the three complexes were found to hydrolyze slowly relative to 
non-fluorinated RAPTA analogues, with equilibrium states being reached after 2 h in 
the cases of [Ru(η6-C6H5F)Cl2(PTA)] (19) and [Ru(η6-1,4-C6H5CH3F)Cl2(PTA)] (21) 
and after 1 day in the case of [Ru(η6-C6H5CF3)Cl2(PTA)] (20). A 5-fold increase in the 
rate of hydrolysis of [Ru(η6-C6H5CF3)Cl2(PTA)] was observed at pH 4.7 compared to 
5.7. It was suggested this increased reactivity may enable selective targeting of more 
acidic cancerous tissue through increased rates of complex activation by hydrolysis. 
After 3 days in 100 mM NaCl solution, free arene ligand is detected to varying extents 
for [Ru(η6-1,4-C6H5CH3F)Cl2(PTA)] (21) and [Ru(η6-C6H5CF3)Cl2(PTA)] (20), 
highlighting the comparatively weak Ru–arene bond as the fluoroarene ligands are 
electron-poor. The pKa values for the protonation of the three [Ru(η6-
fluoroarene)Cl(OH)(PTA)] complexes were calculated to be 8.3 for [Ru(η6-
C6H5F)Cl(OH)(PTA)], 5.5 for [Ru(η6-C6H5CF3)Cl(OH)(PTA)] and 8.9 for [Ru(η6-1,4-
C6H5CH3F)Cl(OH)(PTA)] compared to 8.7 calculated for [Ru(η6-
cymene)Cl(OH)(PTA)], thus highlighting the importance of the choice of arene ligand 
in the design of these complexes. The cytotoxicity of the compounds was screened 
(72 h) against the A2780 cell line revealing a significantly higher cytotoxicity for [Ru(η6-
1,4-C6H5CH3F)Cl2(PTA)] (21) and [Ru(η6-C6H5CF3)Cl2(PTA)] (20) (IC50 = 78 and 38 
μM respectively) relative to [Ru(η6-C6H5F)Cl2(PTA)] (19) and RAPTA-C (1) (IC50 = 507 
and 353 μM, respectively). The cytotoxicity of [Ru(η6-C6H5CF3)Cl2(PTA)] (20) and 
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[Ru(η6-1,4-C6H5CH3F)Cl2(PTA)] (21) is likely related to the increased lability of the 
fluoroarene ligands in these two complexes, as this would lead to increased reactivity 
with biomolecular targets and potentially stronger binding. The lability of the 
trifluorotoluene ligand present in [Ru(η6-C6H5CF3)Cl2(PTA)] (20) was further 
established in a subsequent study that showed on binding to ubiquitin and a double-
stranded oligonucleotide the arene ligand of the complex was readily lost [47]. This 
process resulted in the formation of different biomolecular adducts to those observed 
for RAPTA-C, largely as a result of multidentate binding of the resulting fragment to 
the biomolecular target.  
In related work, examining the necessity of a face-capping aromatic component for 
anticancer activity in RAPTA compounds and other organometallics, a RAPTA 
analogue was prepared with a 1,4,7-trithiacyclononane ligand ([9]aneS3) in place of 
the arene, i.e. [Ru([9]aneS3)Cl2(PTA)] (22) (Figure 8) [48]. 
 
 
Figure 8. RAPTA-derived complexes with the [9]aneS3 ligand replacing the arene [48].  
 
In aqueous solution the complex behaved in a similar manner to the other compounds 
in the RAPTA series with exchange of a chlorido ligand by a water ligand. This product 
was stable over prolonged periods with no loss/exchange of the other ligands. The 
hydrolysis reaction was reversed in the presence of 100 mM NaCl [48]. The impact of 
the complex on cell viability was studied against TS/A and HBL-100 cell lines. Like the 
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original RAPTA series, the complex was only slightly cytotoxic with IC50 values >600 
μM against the TS/A and HBL-100 cell lines. A further analogue containing two 
coordinated PTA ligands, [Ru([9]aneS3)Cl(PTA)2][OTf] (23) (Figure 8), was inert in 
aqueous solution at physiological pH. However, it exhibited a selective mild cytotoxicity 
towards the TS/A cell line (IC50 388 μM) whilst being inactive against the HBL-100 cell 
line (IC50 >1000 μM). This study indicates that the arene ligand may be effectively 
replaced by other face-capping ligands of similar steric demand without significantly 
changing the in vitro activity. 
The RAPTA structure was used as the base for the rational design of two novel 
glutathione transferase P1-1 inhibitors where ethacrynic acid, an effective glutathione 
transferase inhibitor, was tethered with the arene unit of a RAPTA complex [49]. The 
complexes were designed so that upon binding of the ethacrynic acid moiety to the H-
site of the human GST P1-1 enzyme, which is expressed in certain chemoresistant 
tumors, the RAPTA moiety is directed towards the interface of the dimeric protein 
where it could potentially bind to cysteine residues resulting in distortion and 
deactivation of the enzyme. Through competitive inhibition studies it was found both 
complexes are competitive inhibitors of the substrate 1-chloro-2,4-dinitrobenzene. 
Studies showed that both complexes (see Figure 9 for their structures) bind at the 
enzyme H-site and that the ruthenium center plays a major role in inhibition. Through 
mass spectrometric analysis of the GST P1-1 enzyme incubated with the ethacrynic 
acid-RAPTA complex it was found that 1:1 adducts were formed with the enzyme, with 
loss of both Cl ligands, alongside lower mass adducts where the ruthenium fragment 
had been lost (only observed after longer incubation times) leaving an ethacrynic acid-
GST P1-1 adduct. This data was supported by crystal structures of GST P1-1 
incubated with the ethacrynic acid-RAPTA complex (Figure 10). The crystal structure 
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showed that the ruthenium ion was bound to the cysteine residues at the interface of 
the dimer following loss of the chlorido ligands alongside further van der Waal’s 
interactions between the RAPTA arene and PTA ligands with amino acid side chains 
in the vicinity of the dimer interface. The ethacrynic acid moiety was directed into the 
H-site of the enzyme and in a second structure collected after a prolonged incubation 
time, ethacrynic acid was found to bind to the H-site of the enzyme with the metal 
absent. It was postulated that this mechanism could potentially be exploited to 
simultaneously inactivate glutathione transferase P1-1 resistance and release a 
cytotoxic organometallic fragment into the sensitized cell. Subsequent biological 
studies indicated that this two-step process takes place also in vitro [50, 51]. 
 
Figure 9. Structures of ethacrynic acid-functionalised RAPTA derivatives [49]. 
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Figure 10. Stereo picture highlighting the interaction between GST P1-1 and the amide-linked 
ethacrynic acid-RAPTA complex at the GST P1-1 dimer interface. Adapted from ref. [49] © 
2009 John Wiley and Sons.  
 
A range of planar aromatic substituents have been tethered to the arene ring of the 
RAPTA structure (Figure 11), thus introducing a potential DNA intercalator with 
fluorescent properties that may conveniently be utilized to track intracellular 
localization, the first of these comprised of anthracene derivatives linked to the arene 
ring (Figure 11, structure (26)) [52]. The complexes were found to undergo aquation 
in aqueous solution and were assessed for cytotoxicity towards 12 cell lines (72 h). It 
was found that both compounds possessed very low toxicity towards each cell line 
(IC50 >200 μM), in keeping with the low toxicities observed for the parent RAPTA 
analogues. Intracellular localization was monitored in the A549 lung carcinoma cell 
line (24 h incubation, 50 μM, λex 365 nm), however only weak fluorescence was 
observed which precluded identification of precise intracellular localization of the 
complex. 
 
 © 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
 
Figure 11. Functionalization of the arene ligand of RAPTA compounds with anthracene (top) 
[52], pyrene (center) [53] and naphthalimide (bottom) [54].  
 
A similar series of compounds was developed with pyrene moieties tethered to the 
RAPTA arene ligand (Figure 11, structure (27)). These were then encapsulated into a 
water-soluble metalla-cage ([Ru6(η6-p-cymene)6(tpt)2(donq)3]6+) (tpt = 2,4,6-tri-
(pyridin-4-yl)-1,3,5-triazine; donq = 5,8-dioxido-1,4-naphthoquinonato) to circumvent 
the reduced water solubility of the novel RAPTA-pyrene complexes [53]. In cytotoxicity 
assays against the A549, A2780, A2780cisR, Me300 and HeLa cell lines (72 h) the 
three complexes alone were not cytotoxic towards the cell lines at the maximum 
concentration tested (25 μM), with the sole exception of the ether-tethered pyrene 
complex which possessed IC50 values of 15.8, 17.7 and 19.7 μM against the 
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A2780cisR, Me300 and A2780 cell lines, respectively. The host-guest systems were 
significantly more cytotoxic towards all cell lines (IC50 values of 2.0–7.7 μM), however, 
the cage itself also exhibited considerable cytotoxicity towards the cell lines on which 
it was examined (IC50 3.1–4.6 μM). This work illustrated that the introduction of a 
planar aromatic moiety to the arene ligand of the RAPTA structure via a stable tether 
may result in an increase in cytotoxic activity. However, it is unclear whether this effect 
is as a result of modulation of complex lipophillicity, DNA intercalation by the pyrene 
functionality [55], or a combination of both. The formation of the host-guest complex 
with the metalla-cage did result in an increase in cytotoxicity, but this effect is 
dominated by the inherent cytotoxicity of the metalla-cage.   
The naphthalimide functionality, a known DNA intercalator [56], was introduced to the 
arene ligand of the RAPTA structure via short alkyl-chain tethers (Figure 11, structure 
(28)) [54]. These complexes were found to undergo aquation on the same timeframe 
as RAPTA-C and they exhibited high cytotoxicity (72 h) towards the A2780 and 
A2780cisR cell lines (IC50 2.3–9.1 μM). In addition, the compounds were moderately 
more cytotoxic (2- to 3-fold) towards the A2780/A2780cisR cell lines than the non-
cancerous HEK293 cell line. Incubation of the complex with the ethyl-linker between 
the 6-bound arene ring and naphthalimide moiety with ubiquitin led to the formation 
of 1:1 adducts within 1 h (established by ESI MS) and in separate experiments the 
interaction of the naphthalimide group of this complex with ct-DNA was tentatively 
confirmed. Given the known intercalation properties of the naphthalimide group and 
the rapid coordination of the ruthenium center to ubiquitin, it was postulated that the 
high cytotoxicity of these compounds could be related to simultaneous intercalation of 
the naphthalimide moiety with DNA and coordination of the ruthenium ion to protein – 
essentially forming DNA-protein crosslinks.  
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The compounds described above highlight that the cytotoxicity of a RAPTA structure 
may be modulated through the introduction of a planar aromatic moiety tethered to the 
arene ligand. These aromatic systems have the potential to intercalate with DNA, but 
they also result in an increase in lipophilicity of the complex that may also modulate 
their cellular uptake and localization relative to the parent RAPTA complexes. 
Although it is unclear whether the increased cytotoxicity of these compounds is due to 
modified mechanisms of action such as DNA intercalation or due to increased cellular 
uptake and/or modulated intracellular localization, since other very hydrophobic 
RAPTA derivatives such as [Ru(η6-p-cymene)(PPh3)(PTA)Cl]+ (56) display limited 
cytotoxicity (see below) [57], it is tempting to correlate the higher levels of cytotoxicity 
with mechanisms related to the intercalating moiety.  
In a further study that modulated the ability of a RAPTA complex to covalently modify 
biological targets, the DNA-alkylating agent chlorambucil was conjugated with the 
RAPTA scaffold (Figure 12, structure (29)), yielding complexes capable of 
simultaneous DNA alkylation and coordination to proteins [58]. These complexes 
exhibited cytotoxicity in the low to medium M range towards the A2780, A2780cisR 
and MCF7 cell lines (IC50 8.3–45 μM) and one example was more active in cisplatin-
resistant cell lines than chlorambucil, RAPTA-T or a mixture of both. To test the ability 
of the complex to crosslink DNA and protein, model experiments with EtG (EtG = 9-
ethylguanine) and amino acids revealed that coordination of EtG following hydrolysis 
of the complexes was faster than alkylation of EtG by the chlorambucil moiety, but 
there were also signals detected in the mass spectra that were assigned to species 
featuring both EtG and amino acids, demonstrating the feasibility of the approach.   
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Figure 12. Chlorambucil-functionalized RAPTA complexes capable of crosslinking 
DNA and proteins [58].  
 
The effect of introducing enantiomerically pure chiral groups to the arene ligand of the 
RAPTA structure was investigated through the introduction of (R)- or (S)-
methylbenzylamine (Figure 13, structures (30) and (31)) [59]. Two sets of complexes 
were developed – chlorido analogues that readily undergo aquation in aqueous 
solution and oxalato analogues that are more resistant towards ligand substitution in 
water [59]. The cytotoxicity of the complexes was determined against the A2780, 
A2780cisR and HEK293 cell lines (72 h). All complexes were cytotoxic towards the 
A2780 cell line (IC50 8.7–44 μM) and for the oxalato (31) complexes a similar level of 
cytotoxicity was also observed against the A2780cisR and HEK293 cell lines (IC50 21–
33 μM). For the chlorido analogues (30) both enantiomers were essentially non-toxic 
towards the A2780cisR cell line (IC50 396 and 228 μM), however, the R-enantiomer 
was significantly less cytotoxic towards the HEK293 cell line than the S-enantiomer 
(IC50 >1000 μM versus 255 μM), i.e. displaying selectivity cytotoxicity towards the 
cancerous cell lines. Thus, the introduction of the chiral appendage tethered to the 6-
arene ligand, in these examples, dramatically increases cytotoxicity towards 
cancerous A2780 cell lines relative to RAPTA-C and oxaloRAPTA-C as the parent 
analogues that are essentially inactive towards these cell lines. Notably, with the 
chlorido (30) analogues there are cytotoxic differences between the two enantiomers 
 © 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
that can only be attributed to differences in chirality at the arene ring that presumably 
influences binding to biomolecular targets. From this work it is apparent that the 
introduction of chiral substituents represents a promising route to modulate 
activity/selectivity of RAPTA complexes and potentially other classes of ruthenium(II)-
arene compounds; however, it should be noted that on aquation of a chiral RAPTA 
complex, where only one of the chlorido ligands is replaced, diastereomers are formed 
which may react differently with biomolecular targets. 
 
 
Figure 13. Structures of RAPTA compounds with chiral substituents at the arene ligand [59].  
 
The arene ligand of the RAPTA structure has been used as a tethering point to form 
arene-linked dinuclear RAPTA analogues (Figure 14, structures (32) and (33)) [60]. 
These dinuclear compounds were formed using rigid diphenylethylenediamine-based 
linkers to fix the position of the metal centers relative to each other to investigate how 
the conformation of the ruthenium complexes influences their interactions with 
biomolecular targets and subsequent cytotoxicity profiles. Binding studies between the 
chlorido complexes and 5’-GMP or a 13-mer single-stranded oligonucleotide revealed 
facile coordination via chloride-loss and, significantly, arene loss resulting in cleavage 
of the dinuclear complex. In contrast, binding studies with the peptide H-Asp-Ala-Glu-
Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-OH containing three histidine 
residues resulted in 1:1 adducts formed through loss of the chlorido and PTA ligands 
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from the complexes. Electron-transfer dissociation fragmentation MS studies of 
adducts were performed to elucidate the ruthenium ion binding sites. Using this 
technique it was found that very different adducts were formed by the dinuclear 
complexes compared to the mononuclear analogues, with each ruthenium ion of the 
former simultaneously coordinating to one or more histidine residues of the peptide 
whereas for the latter a single ruthenium ion was found to coordinate to one or more 
histidine residues. However, no differences were found in coordination sites or size 
(ion mobility mass spectrometry) of the peptide adducts of the isomeric dinuclear 
complexes. Despite the lack of discrimination observed in analytical studies, an 
assessment of the cytotoxicity of the complexes against the A2780, A2780cisR and 
HEK293 cell lines revealed differences between the activities of these complexes (72 
h). Both mononuclear analogues ((34) and (35)) were essentially non-toxic (IC50 >300 
μM). The dinuclear complexes with the more closed (S,S)- or (R,R)-configuration were 
highly active against all three cell lines (IC50 values (complex concentrations) for 
oxalato analogues of 6–15 μM and for chlorido analogues of 3.7–8.0 μM), whereas 
those with the open (R,S)-configuration were less cytotoxic (IC50 values (complex 
concentrations) for oxalato analogues 19–74 μM, chlorido analogues 20-95 μM). The 
flexible ethylenediamine-linked complex possessed a similar activity to the complex of 
(R,S)-configuration (IC50 values (complex concentrations) oxalato analogues 23–88 
μM, chlorido analogues 35 to >300 μM). This study demonstrated that modulation of 
biological activity is possible through the tethering of two RAPTA complexes, with the 
two ruthenium centers able to simultaneously coordinate to suitable biological targets 
to crosslink and distort their structure leading to novel adducts and increased 
cytotoxicity. The choice of linker is important and may play a crucial role in the type of 
intracellular adducts formed.  
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Figure 14. Arene-linked dinuclear RAPTA derivatives and their mononuclear analogues [60].  
 
Since dinuclear RAPTA compounds tend to be more cytotoxic than related 
mononuclear species a strategy to generate dinuclear species inside cancer cells was 
explored as a route to enhance selectivity [61]. This approach involved the 
development of a RAPTA complex bearing an arene ligand functionalized with a 
bicyclo[6.1.0]non-4-yn-9-ylmethanol moiety (BCN-RAPTA (36); Figure 15). BCN can 
participate in strain-promoted cycloaddition reactions with tetrazines [62], and it was 
found that the combination of a ditetrazine (37) and the BCN-RAPTA derivative in 
biological media resulted in the in situ formation of a dinuclear RAPTA complex (38). 
Combining the ditetrazine and BCN-RAPTA components in vitro in A2780 cells 
resulted in an IC50 value (complex concentrations) of 2.6 μM (72 h), compared to an 
IC50 value of 5.7 μM for a mononuclear tetrazine conjugate analogue formed in situ 
and 12 μM for BCN-RAPTA and >400 μM for the tetrazines. This approach 
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demonstrates that the developing field of strain-promoted cycloaddition reactions may 
offer scope for modification and activation of metal complexes in a biological 
environment. 
 
 
Figure 15. Preparation of a binuclear RAPTA derivative from a tetrazine and BCN-RAPTA 
bearing a bicyclononyne functional group [61].  
 
4.2. Development of RAPTA compounds for conjugation and macromolecular RAPTA 
conjugates 
Modulation of the arene ligand of the RAPTA compounds has been exploited for the 
development of drug targeting/delivery strategies. The first carrier system to be 
developed for the RAPTA compounds is based on human serum albumin (HSA) [63]. 
HSA is known to accumulate in tumors relative to normal tissue, due to the enhanced 
permeability and retention (EPR) effect [64], and previously, it has been shown that 
chlorambucil [65] and paclitaxel [66] tethered to HSA can improve its activity while 
simultaneously reducing toxic side effects. Hydrazine-functionalized recombinant 
human serum albumin (rHSA) allowed a novel RAPTA compound (Figure 16, (39)) to 
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be conjugated through an aldehyde functionality tethered to the arene ligand. The 
resulting RAPTA-rHSA conjugates carry 3 to 4 RAPTA moieties per HSA molecule. 
When screened against the A2780 cell line the hydrazine-functionalized rHSA was not 
cytotoxic at the highest concentration tested (75 μM) and the aldehyde-functionalized 
RAPTA exhibited an IC50 value of 288 μM. In contrast, the rHSA-RAPTA conjugate 
was found to have an IC50 value of 11 μM, significantly more cytotoxic than the 
constituent protein and RAPTA components alone. This increase in cytotoxicity was 
attributed to a combination of facilitated cellular uptake of the conjugate and targeted 
release of the RAPTA compound through cleavage of the hydrazone linkers, possibly 
in the acidic conditions of lysosomes. This targeted-delivery approach does appear to 
offer clear benefits in enhancing the cytotoxicity of a RAPTA compound, with potential 
for in vivo tumor accumulation and targeted cellular release of the cytotoxic drug. 
Indeed, a similar approach has recently been reported for a Ru-based carbon 
monoxide releasing molecule (CORM) with high tumor accumulation observed in vivo 
[67]. The concept of a RAPTA complex able to participate in conjugation/labelling 
reactions was further extended in the development of acetal-containing RAPTA 
structures  [68]. The idea was to allow access to a water-soluble RAPTA structure with 
a less bulky aldehyde functionality (Figure 16, (41)) than the water insoluble 
benzaldehyde-based RAPTA (39).  Chlorido and oxalato analogues of the acetal-
containing RAPTA structures were obtained. The chlorido-analogue was reactive in 
aqueous solution as per the parent RAPTA structures, including rapid aquation and 
reactivity with GSH, whereas the oxalato analogue was essentially inert under the 
same conditions. The acetal group (40) may be converted to an aldehyde (41) in 10 
mM HCl which was found to react readily with an oxime group under mild conditions 
(pH 6), however, ESI-MS analysis of the reaction products revealed the concomitant 
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loss of the oxalato group. In addition, model healthy HEK293 cells were treated with 
the chlorido analogue of the acetal complex and fixed by treatment with HCl to form 
the aldehyde functionality. Treatment of the fixed cells with a hydroxylamine-bearing 
fluorophore resulted in elevated levels of fluorescence relative to control cells, 
indicating the intracellular localization of these complexes may be probed by 
fluorescence microscopy. 
 
Figure 16. Protein conjugation strategies of RAPTA compounds [63, 68, 69].  
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A similar strategy exploited a maleimide-functionalized RAPTA compound (Figure 16, 
(42)) to enable covalent binding to thiol-containing biomolecules [69]. The maleimide-
RAPTA species was found to react rapidly with cysteine, glutathione, N-acetylcysteine 
and N-acetylcysteine methyl ester under physiological conditions (phosphate buffer, 
pH 7.4, 100 mM NaCl, 310 K), with the thiol functionalities reacting selectively via 
nucleophillic addition to the maleimide and not by coordination to the ruthenium center 
(evidenced by NMR spectroscopy and mass spectrometry). The complex was found 
to react with HSA although noticeably slower than with the small molecules. An 
assessment of the cytotoxicity of the complex was performed with CH1 human 
ovarian, SW480 colon and A549 non-small cell lung cancer cells (96 h exposure) and 
was very similar to that observed with RAPTA-C. Consequently, targeting thiol 
functionalities in biomacromolecules represents another viable strategy for the 
preparation of RAPTA-bioconjugates for drug delivery.  
Macromolecular ruthenium conjugates have also been developed that are based on 
synthetic dendrimers and polymers in order to exploit the EPR effect for selective 
tumor accumulation [70]. Dendrimer-based RAPTA delivery systems have been 
devised based on salicylaldimine dendritic ligands where RAPTA moieties with p-
cymene and hexamethylbenzene (hmb) arene ligands were coordinated to dendrimers 
with 4, 8, 16 and 32 coordination points (Figure 17, conjugate (43)), resulting in 
polycationic metallodendrimers with ruthenium centers [71]. The cytotoxicity of the 
dendrimers was evaluated against the A2780, A2780cisR and HEK293 cell lines (72 
h) and compared to mononuclear analogues (Figure 17 (44)). It was found that the 
cytotoxicity of the dendrimers increases as the generation number increases. For 
example, against the A2780 cell line the metallodendrimers with the p-cymene arene 
ligands possessed IC50 values of 174, 9.3, 1.4 and 0.8 μM and for the 
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hexamethylbenzene analogues the values were 8.9, 6.2, 2.9 and 2.0 μM for 
dendrimers with 4, 8, 16 and 32 RAPTA moieties, respectively. When expressing the 
IC50 values as concentration per metal center, the dendrimers with p-cymene ligands 
are more cytotoxic than the mononuclear analogue for dendrimers with 32 RAPTA 
molecules while for lower generations there seems to be only an additive effect. For 
the hexamethylbenzene analogues, the correlation of the IC50 value with the number 
of metal centers is less clear as only small increments in cytotoxicity are observed as 
the generation number increases and the cytotoxicity of the mononuclear analogue is 
relatively high (IC50 of 38, 93 and 60 μM for A2780, A2780cisR and HEK293 cell lines, 
respectively). However, both dendrimer systems were more cytotoxic towards the 
A2780/A2780cisR cell lines than the HEK293 cell line (up to one order of magnitude) 
indicative of a certain level of selectivity whereas the mononuclear species are not 
selective. Incubation of the positively charged dendrimers with pBR322 plasmid DNA 
followed by analysis with gel electrophoresis revealed that incubations with 
dendrimers with 8 or more metal centers resulted in DNA aggregation. The positive 
charge of these dendrimers appears to be important in this aggregation process as 
related neutral metallodendrimers did not significantly aggregate DNA. These results 
show that, like the micellar systems above, the use of macromolecular metallodrug 
delivery systems can lead to increased cytotoxicity and also increased selectivity 
towards cancerous cell lines, and can also potentially alter the mechanism of action of 
the RAPTA structure, especially when release of the RAPTA fragment does not easily 
take place following cellular uptake.   
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Figure 17. Generic structure of dendrimer-based polynuclear RAPTA derivatives and the 
mononuclear reference compound (n = 4, 8, 16, 32; arene = p-cymene, hexamethylbenzene) 
[71]. 
 
RAPTA-C conjugation to a synthetic polymer has been achieved via the reaction of 
the PTA ligands with halogenides to form quaternary ammonium cations [72]. 
Synthetic routes were used to access a linear water-soluble N-(2-
hydroxypropyl)methacrylamide/2-chloroethyl methacrylate (P(HPMA-CEMA)) co-
polymer that could be conjugated to RAPTA complexes. The P(HPMA-CEMA) co-
polymer was accessed through RAFT polymerisation and then modified through 
cleavage of the RAFT end-group. The chloride end-groups were then converted to 
iodide end-groups using the Finkelstein method to yield the modified P(HPMA-IEMA) 
co-polymer. This was then reacted with PTA followed by [RuCl2(η6-p-cymene)]2 to 
yield the water soluble RAPTA-C-containing copolymer, P(HPMA172-IEMA44-(RAPTA-
C-EMA)44) (Figure 18; (45)). Assessment of the cytotoxicity of the RAPTA-C co-
polymer and RAPTA-C was performed against the OVCAR-3 human ovarian cancer 
cell line (SRB assay, 72 h exposure). Both exhibited very low cytotoxicity although the 
RAPTA co-polymer was less cytotoxic than RAPTA-C at equivalent concentrations of 
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ruthenium, postulated to be due to slow diffusion of the polymer across the cell 
membrane and the hydrodynamic diameter of the RAPTA co-polymer being too small 
to activate endocytosis. To improve on the P(HPMA172-IEMA44-(RAPTA-C-EMA)44) 
delivery system, degradable polymeric micelles were used to generate a degradable 
macromolecular drug that undergoes fast endocytosis [73]. An amphiphilic block co-
polymer was obtained from 2-chloroethyl methacrylate and 2-hydroxyethyl acrylate 
(with 1% fluorescein O-methacrylate as a fluorescent tag) as the hydrophilic RAPTA-
bearing block and a biodegradable polylactide (PLA) hydrophobic block (Figure 18; 
bottom right). RAPTA-C was again incorporated into the polymer structure via 
conversion of the polymer chloride groups to iodide groups using the Finkelstein 
reaction, followed by reaction of the polymer with PTA and then addition of the dimer 
[RuCl2(η6-p-cymene)]2. Two RAPTA-containing polymers were obtained, PLA347-b-
P(HEA74-(RAPTA-C-EMA)25) and PLA347-b-P(HEA140-(RAPTA-C-EMA)45) (Figure 18; 
(46)), from which self-assembled micelles were produced [diameter (DLS) 252 nm 
(PDI 0.332) and 555 nm (PDI 0.370), respectively]. It was found that the micelles 
disassembled when incubated with a hydrolase enzyme, indicating that in a cellular 
environment the micelles should degrade to release water-soluble RAPTA-C 
containing polymer fragments. The micelles were evaluated for cytotoxicity against the 
A2780, A2780cisR and OVCAR-3 cell lines (WST-1 assay, 72 h). Both RAPTA-
containing micelles were more cytotoxic than RAPTA-C towards all cell lines. For 
example, IC50 values of 15 and 51 μM were observed against the A2780 cell line 
relative to 271 μM for RAPTA-C.  Fluorescence microscopy indicated that the micelles 
co-localized within the lysosomes (A2780 cell line, 3 h incubation) and ICP-MS 
revealed higher intracellular ruthenium concentrations in cells incubated with the 
micelles compared to RAPTA-C (up to a 12-fold increase in uptake). 
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Figure 18. Synthetic route to PTA-containing polymers and polymers loaded with the RAPTA 
unit via the PTA ligand [72, 73]. 
 
Further studies resulted in the development of cyclic peptide-polymer nanotubes as 
carrier systems of RAPTA-C [74]. Two p(HEA58-co-CEMA10) polymers were coupled 
to a cyclic peptide via an alkyne end-group, followed by exchange of the chloride 
groups of the CEMA side chains to iodide groups using the Finkelstein reaction. 
RAPTA-C was then covalently attached to the polymer via reaction of PTA with the 
iodide side-chains followed by addition of [RuCl2(η6-p-cymene)]2. The self-assembly 
of the RAPTA-C conjugates into nanotubes, via stacking of the cyclic peptides, was 
confirmed by static and dynamic light scattering and also transmission electron 
microscopy, with the hydrodynamic diameter of the observed aggregates being 
reported as between 500 and 1000 nm in solution. The activity of the assembled 
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nanotubes was assessed against the A2780 and A2780cisR cell lines. A [CP-p(HEA58-
co-CEMA10)2] reference assembly, containing no RAPTA-C, was non-toxic (up to 590 
μg mL-1) whilst the NT-RAPTA-C conjugate ((47) – structure not shown) was 
significantly more active against both cell lines (IC50 of 15 μM (A2780) and 22 μM 
(A2780cisR)) compared to RAPTA-C (IC50 of 271 μM (A2780) and 266 μM 
(A2780cisR)). These results likely reflect increased and/or a modulated uptake profile 
of the ruthenium complex when conjugated to the polymer compared to the free 
species.   
Hence, incorporation of RAPTA-C into a suitably sized macromolecular carrier can 
result in increased cellular uptake of ruthenium leading to increased cytotoxicity. Such 
carrier systems should also facilitate the selective targeting of RAPTA to tumors, but 
to date in vivo studies demonstrating enhanced targeting of RAPTA-modified 
macromolecules have not been reported.   
 
4.3. Modulation of the lability of the anionic co-ligands of the RAPTA structure with 
chelating ligands 
The incorporation of chelating ligands in place of the chlorido ligands in the RAPTA 
structure has been used to develop complexes resistant to decomposition in aqueous 
solution (Figure 19). In addition, further chelating ligands have been incorporated to 
modulate the lipophilicity of the complex. 
 
 © 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
 
Figure 19. General scheme highlighting the synthetic route towards RAPTA compounds 
incorporating oxalato or 1,1-cyclobutanecarboxylato ligands (top) [75]. RAPTA compounds 
with chelating oxalato (oxali-RAPTA), 1,1-cyclobutyldicarboxylato (carbo-RAPTA) (middle) 
and acetylacetonato-derived co-ligands (middle and bottom) [76, 77]. 
 
The development of water-stable RAPTA analogues was approached as a route by 
which to circumvent the often difficult problems of identification and characterization 
of aquation products, and thus identification of the active solution species of the 
RAPTA complexes [75]. Reaction of [(η6-p-cymene)RuCl(μ-Cl)]2 with silver oxalate or 
1,1-cyclobutanedicarboxylate followed by PTA addition (Figure 19, top) yielded the 
complexes [Ru(η6-p-cymene)(C2O4)(PTA)] and [Ru(η6-p-cymene)(C6H6O4)(PTA)] 
(Figure 19, (48) and (49), respectively). These complexes were 5- to 10-times more 
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soluble than RAPTA-C in water, and in aqueous solution both complexes were found 
to resist aquation, with no significant ligand exchange occurring in water compared to 
rapid aquation of RAPTA-C. On incubation of both complexes with single-stranded 
DNA for 24 h, followed by analysis with MALDI-TOF, multiple adducts were observed, 
formed largely through loss of the carboxylate ligand with a minor proportion of 
adducts formed through loss of the arene and/or PTA ligands. The pKa of [Ru(η6-p-
cymene)(C2O4)(PTA)] and [Ru(η6-p-cymene)(C6H6O4)(PTA)] were estimated to be 
2.35 and 2.64, respectively, compared to a value of 3.13 for RAPTA-C, indicating that 
like in RAPTA-C the PTA ligands of both complexes are not protonated under 
physiological conditions. Given the similar reactivity of both complexes with chelating 
ligands as RAPTA-C towards ssDNA, it is not surprising that they possess similar 
cytotoxicity profiles as RAPTA-C towards HT29, A549, T47D and MCF7 cell lines (72 
h).  Both compounds and RAPTA-C are mildly cytotoxic towards the HT29 cell line 
(IC50 values of 267, 265 and 436 μM, respectively), and virtually non-toxic towards the 
other three cell lines (IC50 >1000 μM in each case).   
A further strategy employed to modulate the lipophilicity of the RAPTA structure, to 
increase cell uptake and hence cytotoxicity, involved the introduction of 1,3-diketonato 
ligands (R2acac, R = Me, tBu, Ph; Figure 19, structure (50)) of varying lipophilicity, at 
the sites normally occupied by the labile chlorido ligands [76]. The monocationic 
complexes, i.e. [Ru(η6-p-cymene)(R2acac/R2acac-Cl)(PTA)][BF4], slowly undergo 
aquation in 5 mM NaCl aqueous solution and form RAPTA-C in 100 mM NaCl solution. 
The cytotoxicity of the compounds against A2780 human ovarian cancer and A549 
lung carcinoma cell lines (72 h) revealed good activity against the A2780 cell line (IC50 
7–15 μM) and moderate activity against the A549 cell line (50–97 μM), with the 
exception of [Ru(η6-p-cymene)(Me2acac)(PTA)][BF4] (IC50 >2000 μM).   
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A related series of compounds was later reported which incorporated an 
asymmetrically functionalised diketonato ligand (F3C-acac-Ar) within the RAPTA 
structure (Figure 19, (51)); with the CF3 substituent remaining constant whilst the 
aromatic substituent was modulated [77]. This series of compounds was relatively 
stable (<5% conversion to secondary species) for up to 48 h in aqueous solution (3% 
DMSO). The activity of the complexes was assessed (MTT assay, 72 h) against CH1 
ovarian cancer (IC50 8–46 μM), MG63 osteosarcoma (IC50 17–41 μM) and HaCaT 
nonmalignant keratinocytes-derived (IC50 >100 μM except the 4-chlorophenyl-
substituted acac-containing complex (72 μM)) cell lines, with selected examples also 
equally active towards the A2780 and A2780cisR cell lines. These results indicate a 
certain level of selectivity between the cell lines with relatively small differences in 
activity being observed as the structure of the diketonate ligand was modulated. These 
complexes were found, in general, to act via a cytostatic mode of action as indicated 
by selected examples inducing cellular accumulation in the G0/G1 phase, although the 
4-chlorophenyl-substituted acac-containing complex was found to induce apoptosis to 
significant extent. The cytotoxicity of these complexes was not related to the 
generation of reactive oxygen species. 
These studies demonstrate that the labile chlorido ligands of the RAPTA structure may 
be readily exchanged for chelating ligands without loss of reactivity towards model 
substrates, while increasing water solubility and cellular cytotoxicity relative to parent 
RAPTA analogues. It may be envisaged that careful choice of substituents of the 
chelating ligand will allow the ligand exchange rates to be tuned to a cellular 
environment. Moreover, the complex may be endowed with dual functionality through 
the release of the chelating ligand containing a bioactive organic moiety able to interact 
with biomolecular targets. In this regard RAPTA derivatives containing chelating 
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curcuminoid ligands (Figure 20, (52)), where curcumin itself exhibits antitumoral 
effects, have been evaluated for chemotherapeutic properties [78]. 
 
 
Figure 20. Curcuminato complexes derived from the RAPTA structure [78].  
 
A comparison of the aqueous stability of two curcuminato complexes (arene = p-
cymene, R’ = OCH3 or H, X = SO3CF3) was performed in 5 and 100 mM NaCl solutions. 
Whereas the curcuminato complex (R’ = OCH3) was inert to ligand substitution in both 
conditions over 7 days, the curcumoid ligand of the complex with R’ = H was labile, 
being replaced by two chlorido ligands in 100 mM NaCl after 24 hours. Despite this 
difference in behavior with respect to ligand substitution, all complexes were highly 
cytotoxic towards the A2780 and A2780cisR cell lines (IC50 0.14–1.15 and 0.27–1.18 
μM, respectively) and all the complexes were more active than cisplatin and, 
importantly, curcumin (IC50 in A2780 = 8 μM and in A2780cisR = 11 μM). Interestingly, 
all complexes were up to 70-fold less active towards the HEK293 cell line (IC50 4.5–
30 μM), indicative of selectivity for cancer cells. 
Two RAPTA analogues with β-ketoamine ligands coordinated in place of the labile 
chlorido ligands of the RAPTA structure were reported as part of a wider study into the 
biological activity of β-ketoamine ligands coordinated to ruthenium (Figure 21, (53)) 
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[79]. The cytotoxicity of the two RAPTA derivatives, which were sparingly soluble in 
aqueous solution, and the β-ketoamine ligands was determined against the A2780 
and A2780cisR cell lines (72 h). The β-ketoamine ligand containing a naphthyl-
substituent was cytotoxic towards both cell lines (IC50 values of 14.4 and 14.0 μM in 
A2780 and A2780cisR cell lines, respectively), whereas the ligand with the phenyl-
substituent was comparatively non-toxic (IC50 values of 275 and 271 μM in A2780 and 
A2780cisR cell lines, respectively). The complex with the coordinated napthyl-
substituted β-ketoamine ligand yielded IC50 values of 6.0 and 6.1 μM against the 
A2780 and A2780cisR cell lines, respectively, whereas the complex with the 
coordinated phenyl-substituted β-ketoamine ligand yielded IC50 values of 18.9 and 
19.5 μM. These complexes are equally active in the A2780 parent cell line and the 
cisplatin-resistant strain, indicating they are unaffected by cisplatin-resistance 
mechanisms. The bulky β-ketoamine ligands appear to increase complex lipophilicity 
relative to RAPTA-C and this likely plays a role in their high activity through increased 
cellular uptake and modulation of cellular localization. However, for the complex with 
the napthyl-substituted β-ketoamine ligand the high cytotoxicity of the ligand itself 
probably contributes to the observed cytotoxicity of the complex whereas the complex 
with the phenyl-derived β-ketoamine ligand possesses a high cytotoxicity not 
apparently related to the ligand.     
 
Figure 21. RAPTA compounds with chelating N,O β-ketoamine (R = phenyl, naphthyl) [79] 
and N,N pyrazolo-[3,4-d]pyrimidine co-ligands [80]. 
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Two RAPTA analogues were also reported as members of a wider series in a study 
developing organometallic inhibitors of the human A3 adenosine receptor (hA3AR), 
which is a prospective chemotherapeutic target in the treatment of cancer and is 
overexpressed in various tumors [80]. The complexes incorporated chelating 
pyrazolo-[3,4-d]pyrimidine ligands (Figure 21, (54) and (55)) in place of the chlorido 
ligands of the RAPTA structure to create novel organometallic inhibitors based on the 
pyrazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pyrimidine scaffold, examples of which are known 
to inhibit the hA3 receptor in the nM range. The binding affinities of the complexes were 
assessed against human hA1, hA2 and hA3 adenosine receptors expressed in Chinese 
hamster ovary (CHO) cells. The RAPTA-based inhibitors displays slightly lower 
binding affinities towards the receptors relative to analogues bearing a chlorido ligand 
in place of the PTA ligand, attributed to the increased steric bulk of the inhibitor due to 
the PTA ligand. However, these RAPTA-based inhibitors display selective inhibition 
towards the hA3 receptor highlighting the value in modulating the ligands around the 
ruthenium ion to tune selectivity for a receptor of interest. 
 
4.4. Introduction of additional phosphine ligands into the RAPTA framework 
Other studies focusing on the development of more hydrophobic RAPTA analogues 
based on the substitution of one chloride ligand by a phosphine ligand have been 
undertaken in an attempt to increase their uptake into cancer cells and thus modulate 
their cytotoxicity [57]. Two chiral-at-metal center RAPTA complexes were reported as 
racemic mixtures, i.e., analogues of RAPTA-C and [Ru(η6-C6H5CH2CH2OH)Cl2(PTA)] 
with a PPh3 ligand in place of one chlorido ligand (Figure 22, (56) and (57)). The 
cytotoxicity of the novel compounds was assessed against the TS/A and HBL-100 cell 
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lines (72 h). The increased hydrophobicity of [Ru(η6-
C6H5CH2CH2OH)Cl(PPh3)(PTA)][BF4] (57) resulted in an increase in cytotoxicity 
towards both the TS/A and HBL-100 cell lines (IC50 124 and 82 μM, respectively) 
relative to the inactive [Ru(η6-C6H5CH2CH2OH)Cl2(PTA)] (10) analogue (IC50 >300 μM 
in both cell lines). This increase in cytotoxicity was mirrored by increased uptake into 
TS/A cells relative to [Ru(η6-C6H5CH2CH2OH)Cl2(PTA)]. Relative to RAPTA-C (1), 
[Ru(η6-p-cymene)Cl(PPh3)(PTA)][BF4] (56) was more active against the HBL-100 
healthy cell line (IC50 >300 vs. 37 μM, respectively) suggesting that increased 
hydrophobicity decreases cancer cell selectivity. In protein binding experiments it was 
observed that [Ru(η6-C6H5CH2CH2OH)Cl(PPh3)(PTA)][BF4] (57) was less reactive 
towards ubiquitin and cytochrome-c than RAPTA-C, and more reactive towards a 14-
mer oligonucleotide. The low aqueous solubility of [Ru(η6-
cymene)Cl(PPh3)(PTA)][BF4] (56) prevented a similar analysis. This work exemplified 
that by tuning the steric bulk and hydrophobicity of the RAPTA complexes selectivity 
for reactivity towards nucleic acid or protein targets could be modulated, leading to 
increased cytotoxicity but reduced selectivity. These ideas were subsequently 
confirmed in binding studies to chromatin that compare RAPTA-C with [Ru(η6-p-
cymene)(en)Cl]+ (see below) [81].  
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Figure 22. The RAPTA framework modified with additional phosphorus-containing ligands [57, 
82, 83]. 
 
In contrast, the novel bis-phosphine complex, [Ru(η6-cymene)(PPh2(o-C6H4O)-κ2-
P,O)(PTA)]+ (Figure 22, (58)), containing the chelating phosphine group ortho-oxy-
triphenylphosphine, was inert in aqueous solution, essentially unreactive towards a 
single stranded oligonucleotide and only mildly reactive towards ubiquitin compared 
to RAPTA-C [82]. Despite being largely inert under physiological conditions, this 
complex was moderately cytotoxic towards the A2780 cell line (72 h, IC50 = 138 μM). 
It was postulated that this activity may be due to non-covalent interactions mediated 
by the chelating phosphine ligand. 
A series of RAPTA compounds of the general formula [Ru(η6-arene)Cl(PR3)(PTA)] 
[BF4] (arene = p-cymene or 4-phenyl-2-butanol; PR3 = PPh2(p-C6H4C2H4C8F17), 
PPh(p-C6H4C2H4C8F17)2, P(p-C6H4C2H4C6F13)3, PPh3 or P(p-C6H4F)3, Figure 22, 
structures (59) and (60)) were developed to assess the anticancer potential of RAPTA-
type complexes in thermotherapy [83]. Thermotherapy (or hyperthermia) is used to 
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improve drug efficacy by selective heating of the tumor to typically 41–42 °C; however, 
the small molecule drugs used in this duotherapy are not designed for such an 
application, e.g., cisplatin is widely used [84]. Phosphine ligands bearing 
perfluorinated chains were incorporated into the RAPTA structure to endow the 
complexes with thermomorphic properties since highly fluorinated compounds are 
known to undergo large changes in solubility with small changes in temperature [85]. 
The aim of combining the RAPTA structure with perfluorinated substituents was to 
obtain complexes with increased solubility on raising the temperature, i.e., so that at 
37 °C they are insoluble and cannot penetrate cells whereas at 41–42 °C they 
solubilize and can cross cell membrane (specifically at the heated tumor site). The 
majority of complexes had no or very limited water solubility, however, the aquation 
behavior of the water-soluble compound [Ru(η6-4-phenyl-2-butanol)Cl(PPh2(p-
C6H4C2H4C8F17)(PTA)][BF4]  (Figure 22, bottom) was examined in D2O by NMR 
spectroscopy. The complex undergoes ligand exchange over several hours to yield 
[Ru(η6-4-phenyl-2-butanol)(D2O)(PPh2(p-C6H4C2H4C8F17)(PTA)]2+, revealing the 
lability of the chlorido ligand (addition of 100 mM NaCl displaced the aqua ligand to 
regenerate the original complex). The solubility of the compounds as a function of 
temperature was assessed and the solubility of [RuCl(η6-4-phenyl-2-butanol)(PPh2(p-
C6H4C2H4C8F17)(PTA)][BF4]  was found to increase from 2.5 mM at 20 °C to 30 mM at 
45 °C, while [Ru(η6-cymene)Cl(PPh2(p-C6H4C2H4C8F17)(PTA)]+ and [Ru(η6-4-phenyl-
2-butanol)Cl(PPh2(p-C6H4C2H4C8F17)2)(PTA)]+  were essentially insoluble at 37 °C but 
possessed a solubility in excess of 0.3 mM at 42 °C. The cytotoxicity of the compounds 
was assessed against the A2780 and A2780cisR cell lines (72 h). Against the A2780 
cell line the fluorous-chain compounds exhibited high to moderate cytotoxicity (IC50 
1.5–97 μM) and in general only a slight decrease in activity against the A2780cisR cell 
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line (IC50 5 to >200 μM) was observed. Compared to [Ru(η6-4-phenyl-2-
butanol)Cl(PPh3)(PTA)]+ with IC50 values of 184 μM in A2780 and >200 μM in 
A2780cisR, the fluorous-chain analogues are significantly more cytotoxic. The 
cytotoxicity of [Ru(η6-4-phenyl-2-butanol)Cl(PPh2(p-C6H4C2H4C8F17)(PTA)][BF4]  and 
[Ru(η6-cymene)Cl(PPh2(p-C6H4C2H4C8F17)(PTA)][BF4], exhibiting temperature-
dependent solubility, were evaluated against the A2780 and A2780cisR cell lines at 
37 °C and also under identical conditions except with a 2 h incubation time at 42 °C 
following addition of the compound. Both compounds were slightly more cytotoxic 
towards both cell lines after the brief heating period (e.g., the IC50 of [Ru(η6-
cymene)Cl(PPh2(p-C6H4C2H4C8F17)(PTA)][BF4]  against the A2780 cell line was 3 μM 
and 2 μM at 37°C and 42°C, respectively). A further series of complexes, featuring 
imidazole ligands functionalized via click chemistry with a range of hydrophobic tails 
(Figure 23, structures (61) and (62)), was also reported [86]. The p-cymene 
compounds (with the exception of the amine-bearing analogue) were poorly soluble in 
water. The stability of the soluble compounds in aqueous solution was examined by 
NMR spectroscopy, showing the complexes to be stable with no changes to the 
spectra after addition of 100 mM NaCl over a period of 72 hours. The cytotoxicity of 
the compounds was examined in the A2780 and A2780cisR cell lines to yield a range 
of IC50 values ranging from modestly cytotoxic to essentially inactive (34 to >300 μM). 
In general, compounds with a more positive log Pow coefficient were more active 
although there are several exceptions. Compounds with the phenyl-2-ethanol arene 
ligand were also found to exhibit cytotoxic selectivity towards the A2780/A2780cisR 
cell lines (IC50 = 50–144 μM) compared to the healthy HCEC endothelial cell line (IC50 
>500 μM).  These results indicated that the increased solubility of the compounds at 
elevated temperatures may lead to more efficacious compounds and, subsequently, 
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this concept was extended to a new series of compounds that display remarkable 
cytotoxic discrimination at 37 °C and 42 °C [87]. 
 
 
Figure 23. RAPTA-type compounds with imidazole-derived co-ligands modified through click 
chemistry [86].  
 
4.5. RAPTA-type compounds with 5-coordinated cyclopentadienyl rings 
Ruthenium cyclopentadienyl compounds form a growing class of compounds being 
evaluated for their in vitro cytotoxicity. Several examples of these compounds have 
been developed with a PTA ligand incorporated into the structure forming structures 
closely related to the early RAPTA compounds (Figure 24, structures (63)-(66)).  
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Figure 24. RAPTA-derived cyclopentadienyl-Ru(PTA) complexes (R = H, Me; X = Cl, I) [88, 
89].  
 
The antiproliferative activity of piano-stool compounds containing cyclopentadienyl 
ligands was initially reported for [Ru(5-C5R5)Cl(PTA)2] (R = H, Me) compounds (63) 
[88]. [Ru(5-C5H5)Cl(PTA)2] was inactive at any tested concentration against the TS/A 
murine adenocarcinoma cell line whereas [Ru(5-C5Me5)Cl(PTA)2] exhibits 
antiproliferative effects starting at a concentration of 10 μM (an IC50 value was not 
specified). The interaction of [Ru(5-C5H5)Cl(PTA)2] and the related compounds 
[Ru(5-C5H5)Cl(mPTA)2][CF3SO3]2 (64), [Ru(5-C5H5)Cl(PPh3)(PTA)] (65) and [Ru(5-
C5H5)Cl(mPTA)(PPh3)][CF3SO3] (66) (mPTA = N-methyl-1,3,5-triaza-7-
phosphaadamantane; Figure 24) with DNA was probed via mobility shift assays [89]. 
Retardation of scDNA in mobility shift assays was observed in each case when 
incubated with the complexes, indicative of coordination to the complexes and 
destabilization of the duplex scDNA. Iodido analogues of the complexes, i.e., [Ru(5-
C5H5)I(PTA)2], [Ru(5-C5H5)I(PPh3)(PTA)], [Ru(5-C5H5)I(mPTA)2][CF3SO3]2 and 
[Ru(5-C5H5)I(mPTA)(PPh3)][CF3SO3] (Figure 24), do not interact with DNA indicating 
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the Ru–I bond is more stable and cannot be displaced by N-containing nucleophiles 
of DNA. Cell-based cytotoxicity assays were not performed with these compounds, 
but as shown from the earlier report on [Ru(5-C5H5)Cl(PTA)2], the ability of a complex 
to coordinate to DNA does not necessarily translate to antiproliferative activity. 
The cytotoxicity of two compounds constructed with cyclopentadienyl rings that were 
heavily functionalised with sterically bulky, lipophillic substituents (Figure 25, (67)) was 
evaluated on the A2780 and A2780cisR cell lines, 72 h exposure) [90]. Both 
compounds displayed a similar level of cytotoxicity towards both cell lines (IC50 = 4-10 
μM) and are significantly more active than [Ru(5-C5H5)Cl(PTA)2]. The increased 
activity of these two complexes is likely due to the increased lipophilicity of the 
complexes as well as facilitated exchange reactions due to the presence of the bulky 
cyclopentadienyl-type ligands.   
 
 
Figure 25. Ru complexes with sterically bulky Cp derivatives (R = Me, Et) [90].  
 
Further studies extended the series of ruthenium(II)-cyclopentadienyl complexes to 
include examples with three phosphine co-ligands (Figure 26) and examined their 
interactions with scDNA using the shift mobility assay [91]. The chiral complex [Ru(5-
C5H5)(mTPPMS)(PTA)(PPh3)] (68) (mTPPMS = Ph2P(3-OSO2C6H4)–) was found to 
retard scDNA whereas no interactions with scDNA were observed for [Ru(5-
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C5H5)(mTPPMS)(mPTA)(PPh3)][CF3SO3] (69), [Ru(5-C5H5)(mTPPMS)(PTA)2] (70), 
Na[Ru(5-C5H5)(mTPPMS)2(PTA)] (71) and [Ru(5-C5H5)(mTPPMS)2(mPTA)] (72). 
These complexes do not undergo ligand exchange reactions in water implying that the 
metal center may not react with the N-based nucleophilic groups of DNA. For [Ru(5-
C5H5)(mTPPMS)(PTA)(PPh3)] (68) and other mTPPMS-containing triphosphine 
complexes interacting with DNA [91] it was postulated that the mTPPMS ligand may 
be responsible for the observed interactions. This hypothesis was supported by the 
observation that mTPPMS alone was able to cleave DNA under the incubation 
conditions. 
 
 
Figure 26. Structures of inert RuCp compounds featuring three phosphine co-ligands [91]. 
 
A series of complexes of formula {[Ru(Cp)(PTA)2]xL} and {[Ru(Cp)(PPh3)(PTA)]xL} (L 
= thiopurine derived ligands, x = 1) ((73)-(76)) and dinuclear analogues (L = bis-
thiopurine ligands, x = 2) ((77) and (78)) (Figure 27) was reported [92]. The 
mononuclear ruthenium complexes were stable in solution for more than 2 days. The 
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measured log POW values reflect the nature of the phosphine ligands (2 PTA versus 1 
PTA and 1 PPh3) and also the lipophillicity of the thiopurine ligand substituents. The 
mononuclear complexes with two PTA ligands are less cytotoxic (IC50 >50 μM) 
towards T2 (174 x CEM.T2) cells than those bearing one PTA ligand and one PPh3 
ligand, where the most cytotoxic compound (IC50 2–10 μM) was the one with the 
highest log POW value (1.54). All complexes were less cytotoxic towards the cisplatin-
resistant SKOV3 cell line (IC50 >50 μM) and the dinuclear compounds were all shown 
to have poor antiproliferative activities. 
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Figure 27. Mono- and dinuclear RuCp complexes with thiopurines (R = Me, CH2Ph; n = 1, 2, 
3) [92].  
 
Ruthenium cyclopentadienyl complexes with alkylated PTA ligands (Figure 28, 
structure (79)) were evaluated for antiproliferative activity (72 h) against the SKOV3 
and SW480 cell lines and compared with [Ru(5-C5H5)(PPh3)(PTA-Me)Cl]I and 
[Ru(5-C5H5)(PPh3)(PTA)Cl] [93]. The ligands (PTA-Me)I and (PTA-C12H25)PF6 were 
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found to have low toxicity against the SKOV3 cell line (IC50 >50 μM) whereas the PTA-
C16H33+ and PTA-C18H37+ ligands were more cytotoxic with IC50 values of 36 and 42 
μM, respectively. The complexes were more cytotoxic than the ligands with IC50 values 
of 35, 9.1, 9.6 and 9.5 μM for [Ru(5-C5H5)(PPh3)(PTA-Me)Cl]I, [Ru(5-
C5H5)(PPh3)(PTA-C12H25)Cl]PF6, [Ru(5-C5H5)(PPh3)(PTA-C16H33)Cl]PF6 and [Ru(5-
C5H5)(PPh3)(PTA-C18H37)Cl]PF6, respectively. Similar cytotoxicities were obtained 
against the SW480 cell line, with the longer chain PTA-bearing complexes being more 
cytotoxic than the complex with the methylated PTA ligand. In contrast, [Ru(5-
C5H5)(PPh3)(PTA)] was not cytotoxic (IC50 >100 μM in both cell lines). It is likely that, 
relative to complexes bearing PTA or PTA-Me ligands, the cellular uptake, localization 
and biomolecular interactions of those complexes bearing cationic amphiphilic PTA 
ligands is significantly modulated, leading to the increased cytotoxicity.  
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Figure 28. Functionalization of the PTA ligand in RuCp complexes (n = 11, 15, 17) [93, 94]. 
 
Structurally related PTA analogues of acetylcholine and trimethylglycine, two model 
compounds containing quaternary ammonium groups [94], were used to generate 
[Ru(5-C5H5)(PPh3)(PTA-CH2CH2CO2CH3)Cl][PF6] (80) and [Ru(5-
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C5H5)(PPh3)(PTA-CH2CO2Et)Cl]Cl (81) (Figure 28, bottom), which were evaluated for 
antiproliferative activity against A2780, SKOV3 and K562 cells (72 h). Both 
compounds were highly cytotoxic towards all three cancer cell lines with IC50 values 
in the ranges of 4.7-5.1 and 5.5-8.3 µM, respectively. The modified PTA ligands were 
designed to be structural analogues of naturally occurring quaternary ammonium 
groups, including the neurotransmitter acetylcholine. Further work is required to 
determine if there is any specific activity resulting from the structural similarity of the 
PTA-derived ligands to these naturally occurring ammonium ions or if the high 
cytotoxicity is simply due to modulation of the amphiphilic nature of the ruthenium 
complex. 
 
5. Mechanistic studies 
5.1. Plasma protein interaction of RAPTA compounds 
Human serum transferrin and human serum albumin are believed to play significant 
roles in the modes of action of anticancer metallodrugs, both being considered for the 
transport, delivery and/or storage of various metallodrugs. Albumin binds to a wide 
range of drugs immediately after their intravenous application [95], and transferrin is 
an iron-binding blood plasma glycoprotein responsible for controlling the level of free 
iron in biological fluids [96]. Although the iron affinity of the protein is extremely high 
other metals can bind to transferrin and due to the overexpression of transferrin 
receptors on tumor cells, transferrin-drug delivery is an attractive approach for targeted 
cancer therapy. Mass spectrometric analysis of albumin and transferrin drug adducts 
is hampered by their high molecular weight (67 and 80 kDa, respectively). To 
overcome this problem, low molecular weight proteins or peptides mimicking the active 
sites of albumin and transferrin residues tend to be used. Binding studies of RAPTA-
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T (3) to apo-Tf and a small peptide which contains His249 involved in iron binding to 
transferrin indicate the presence of mono-ruthenated [Ru(6-arene)]-apo-Tf species 
[97]. MS analysis of the RAPTA-bound model peptide adducts demonstrated that a 
histidine residue is the major binding partner and, as expected, cysteine is also 
involved in the binding, although to a lesser extent. Notably, the affinity of RAPTA-T 
for albumin and transferrin is significantly higher than that of cisplatin, possibly 
because RAPTA compounds can react directly with biomolecular targets without 
forming aqua adducts (see section 4.3.). It was also shown that RAPTA complexes 
bind with a higher affinity to holo-transferrin in comparison with apo-transferrin and 
albumin, whereas cisplatin was non-selective and had a similar affinity to all the 
proteins used in the study.  
 
5.2. Subcellular localization 
Once a compound has been taken up by a cancer cell, a knowledge of its subcellular 
localization helps to provide information on the mode of drug action. In this regard ICP-
MS has been used to determine cellular uptake and localization in cells incubated with 
RAPTA-T [98]. Ruthenium was detected in the cytoskeleton and membranes, which is 
not unexpected as cytoskeletal proteins are crucial for metastatic processes and 
RAPTA complexes reduce metastasis. It was found that RAPTA-T uptake into cancer 
cells is dependent on the cell type, accumulating in cisplatin-resistant cells to a greater 
extent than in cisplatin-sensitive cells, and indicating that RAPTA-T uptake is not 
influenced by cisplatin-related resistance mechanisms. RAPTA-T was found to have 
a high preference for the particulate fraction containing organelles, i.e., mitochondria, 
endoplasmic reticulum, Golgi apparatus and lysosomes. In the cisplatin-resistant cell 
line this preference is reduced and shifted towards the nucleus and cytosol [98]. 
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Notably, the amount of RAPTA-T in mitochondria is significantly higher than the 
amount of cisplatin in both cisplatin-sensitive and resistant cells, where no platinum 
was detected.  
 
5.3. Reactions with potential intracellular targets 
5.3.1. DNA as a suggested target 
The early report of pH-dependent pBR322 DNA damage mediated by RAPTA-C (1) 
demonstrated the ability of the RAPTA compounds to interact with and distort DNA 
[29], and led to DNA being considered as a potential intracellular target of the RAPTA 
compounds. To probe this hypothesis, numerous mechanistic, analytical and 
theoretical studies were performed. Binding studies with 14-mer DNA oligonucleotides 
by mass spectrometry showed that RAPTA-C and [Ru(η6-p-cymene)Cl2(PTA-Me)]Cl 
(5) coordinate to DNA via the loss of labile chlorido ligands and, following prolonged 
incubation, loss of the p-cymene ligand with retention of the PTA ligand is observed 
[99]. The loss of p-cymene may lead to the formation of -bound DNA adducts via 
coordination of aromatic rings of nucleobases to the ruthenium center although DFT 
computations indicated that -binding is not favored energetically. It is more likely that 
single-stranded oligomers wrap around the metal center with subsequent formation of 
multiple coordination bonds, leading to significant distortions of the oligonucleotide.   
The high reactivity of RAPTA-C to dGMP in acidic conditions was confirmed by CZE-
ICP-MS experiments. pH dependent binding of RAPTA-C to dGMP was observed, 
with a considerably higher reactivity at pH 6.0 compared to pH 7.4, implying that 
binding would be favoured in the more acidic (hypoxic) environment of tumors and 
endowing the compound with a built in selectivity mechanism [100]. 
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Computational studies suggest that under acidic conditions RAPTA complexes exist 
mainly in the mono-aqua form, i.e., [Ru(η6-arene)Cl(H2O)(PTA)]+, and since the aqua 
ligand is labile the complexes react more efficiently with potential biomolecular targets 
at low pH values [35]. Adducts of RAPTA-B, RAPTA-C and [Ru(η6-p-cymene)Cl2(PTA-
Me)]+ with various DNA model compounds (9-methylguanine, 9-methyladenine, 
guanosine, inosine, hypoxanthine, adenosine, cytidine, thymidine and uridine) in 
aqueous conditions were characterized by electrospray ionization mass spectrometry 
(ESI-MS) and 1H NMR spectroscopy [101]. The most abundant signals could be 
attributed to mono-chlorido complexes with purine bases or nucleosides coordinated 
via N7. The N7 position on guanine appeared to be the preferred coordination site – a 
conclusion substantiated later by top-down tandem mass spectrometry studies that 
identified guanine as the preferred coordination site of RAPTA-T with double stranded 
oligonucleotides [102]. However, it should be noted that adducts with adenine or 
thymine were also observed, although to a lesser extent. 
The DNA binding mechanisms of RAPTA-C, RAPTA-B and [Ru(η6-p-cymene)(en)Cl]+ 
were compared using classical and QM/MM molecular dynamics simulations using a 
12 base-pair DNA duplex as a model target [103]. It was shown that these compounds 
bind to the major groove of DNA, with the two different compound families inducing 
different local and global changes in the DNA structure. The calculations demonstrated 
that RAPTA-C induced DNA bending towards the major groove without breaking 
Watson-Crick base pairs or intercalating between them, which is different from [Ru(η6-
cymene)(en)Cl]+ for which breakage of a Watson-Crick base-pair was found. 
 
The nature of interactions of RAPTA-C and carbo-RAPTA-C (Figure 19, (49)) with the 
DNA sequence of the human breast cancer suppressor gene 1 (BRCA1) was 
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investigated using conformational analysis of ruthenated DNA, crosslinking assays 
and semi-quantitative PCR [104]. In accordance with the results described above, it 
was shown that ruthenation induced unwinding of the supercoiled DNA. These studies 
revealed that RAPTA complexes preferentially bind to adenine and guanine.  
The ability of four RAPTA complexes (arene = benzene, toluene, p-cymene, 1,3,5-
iPr3C6H3) to inhibit transcription in mammalian cells was investigated through 
transfection of a ruthenated pCMV-GLuc plasmid (encoding the gaussia luciferase 
(GLuc) reporter gene) followed by quantification of the expressed levels of GLuc in 
transfected cells [105]. It was found that the RAPTA complexes with the bulkier arene 
ligands exhibited reduced reactivity towards the plasmid, most likely due to steric 
repulsion. Ruthenation of the plasmid was found to inhibit transcription effectively in 
live mammalian cells (HCT-116) only at high Ru-DNA crosslink levels where, perhaps 
surprisingly, those RAPTA complexes with the more sterically demanding arene 
ligands were less effective. For example, the reduction of transcription to the level of 
50% of non-ruthenated controls required 74, 87, 112 and 302 Ru-DNA crosslinks per 
plasmid for RAPTA-B, RAPTA-T, RAPTA-C and [Ru(η6-1,3,5-iPr3C6H3)(PTA)Cl2], 
respectively. It was postulated that the less efficient inhibition by the more bulky 
complexes is related to more efficient DNA repair of the bulky RAPTA-DNA adducts. 
This was supported by observation that the transcription recovery rates recovered 
more rapidly as the steric bulk on the η6-arene increased, potentially due to enhanced 
recognition by DNA repair proteins of the DNA distortions induced by the more bulky 
RAPTA adducts.  
 
5.3.2. RAPTA and protein interactions 
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Although RAPTA complexes can readily react with DNA models under physiologically 
relevant conditions there is not a strong correlation between this reactivity and 
cytotoxicity towards cancer cell lines. This limited correlation led to the investigation of 
proteins as potential targets of RAPTA-based compounds.  
Initial studies showed that RAPTA compounds readily bind peptides and proteins such 
as glutathione [106], lysozyme [107], ubiquitin [108], cytochrome-c [107, 108], 
superoxide dismutase [108], the human serum proteins albumin and transferrin [97] 
mentioned in section 5.1, poly(adenosine diphosphate (ADP)-ribose) polymerases 
(PARPs) [109], and metallothioneins [110]. The wide scope of reactivity is perhaps not 
unexpected given the number and availability of nucleophilic atoms in protein systems 
that can coordinate to the ruthenium center through ligand exchange reactions. 
Indeed, cisplatin can bind to essentially the same range of proteins, but RAPTA-C was 
more selective and able to discriminate between proteins presumably due to its greater 
three-dimensional steric bulk.  
 
5.3.2.1. Interactions with model proteins 
Ubiquitin (ub) and cytochrome-c (cyt) have been widely used as model proteins in ESI-
MS experiments to study protein–metallodrug adduct formation due to their stability 
and low molecular weight [111]. RAPTA-C reacts with ubiquitin to afford mono-
ruthenated adducts, the dominant species being assigned to [ub + Ru(6-p-cymene)] 
[108]. [Ru(η6-C6H5CF3)(PTA)Cl2] (20), with a labile arene ligand behaves significantly 
different from all other members of the RAPTA family [47], forming unusual adducts 
with ubiquitin. For example, after 1 day of incubation the most abundant signals were 
assigned to [ub + Ru(PTA)(H2O)x] (x = 0–2) and ubiquitin adducts with only a 
ruthenium ion were also observed. As glutathione (GSH) is a high affinity metal binder, 
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it may induce release of metallodrugs from their conjugates with biological targets 
through competitive binding. Notably, GSH was shown to slowly displace the RAPTA 
moiety from RAPTA-ub adducts [106]. 
The reaction of cyt with RAPTA-C results in extensive protein metallation, whereas 
only moderate or low ruthenation was observed with carbo-RAPTA-C (49) and oxali-
RAPTA-C (48) (Figure 19) [107], correlating with the ability of the complexes to release 
their leaving groups upon hydrolysis [112]. For RAPTA-C both mono-ruthenated 
species, namely [cyt + [Ru(6-cymene)] and [cyt + [Ru(6-p-cymene)(PTA)], and bis-
ruthenated species with either two [Ru(6-p-cymene)] fragments or one [Ru(6-p-
cymene)] and one [Ru(6-p-cymene)(PTA)] fragment, were detected.  In contrast, one 
adduct with carbo-RAPTA-C did not retain the arene ligand and bis-ruthenated species 
were not detected. Under the same conditions only one Ru-containing peak with very 
low intensity was observed with oxali-RAPTA-C (48), which was attributed to a mono-
ruthenated species with a [Ru(6-p-cymene)] fragment. Under similar conditions 
cisplatin forms mono-, bis- and tris-adducts with cyt [113], and [Ru(6-p-
cymene)(en)Cl]+ forms exclusively mono-ruthenated species. A bottom-up method 
(MS analysis of peptides obtained from the enzymatic digestion of the metallated 
protein) was used to identify the likely RAPTA-C binding sites on cyt [107], identifying 
His33 as the major interaction site for RAPTA-C (compared to Met65 as the primary 
binding site for platinum complexes). 
In order to study competitive binding to proteins, RAPTA-C was incubated with a 
mixture of ub, cyt and superoxide dismutase [108] and it was found to coordinate to 
both ubiquitin and cytochrome-C, which matches well with the data obtained for the 
binding studies to single proteins [108], with only limited binding to superoxide 
dismutase.  
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RAPTA-C binding to metallothioneins was also studied by ESI-MS [110] as this protein 
is implicated in the homeostasis of essential metals and detoxification of heavy metals 
[114]. Moreover, the overexpression of metallothioneins serves as a marker for tumor 
progression and metallodrug resistance [115]. Indeed, metallothionein-2 acts as an 
effective intracellular scavenger of platinum(II) drugs by forming stable adducts [116]. 
RAPTA-C formed mono-ruthenated adducts of metallothionein-2 with the concomitant 
displacement of zinc ions that usually bind to the Cys residues in the protein. In the 
presence of ubiquitin and glutathione the ruthenium fragment was removed from 
metallothionein-2 with ubiquitin stripping ruthenium-metallothionein adducts much 
more efficiently, potentially allowing RAPTA compounds to overcome metallothionein-
based drug resistance. 
RAPTA complexes were found to inhibit cathepsin B, thioredoxin reductase [117] and 
poly(adenosine diphosphate (ADP)-ribose) polymerases (PARPs) [109]. The role of 
thioredoxin reductase in cancer is ambiguous, protecting highly proliferating cells from 
the immune system, and up-regulation of thioredoxin reductase might contribute 
towards drug resistance [118]. Several RAPTA compounds were screened towards 
cytosolic or mitochondrial thioredoxin reductases [117]. None of the RAPTA 
compounds evaluated were effective inhibitors of mitochondrial thioredoxin reductase 
although inhibition of cytosolic thioredoxin reductase was more pronounced (45–200 
µM), but probably of little relevance in vivo. RAPTA complexes with sterically 
demanding arenes are less effective inhibitors, presumably as the enzyme cannot 
easily accommodate the bulky substituents. Interestingly, carbo-RAPTA-C, which 
does not contain labile chlorido ligands in its structure, was a more effective inhibitor 
than RAPTA-C. The same series of RAPTA compounds were effective inhibitors of 
cathepsin B, whose overexpression correlates with metastatic and invasive processes 
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[117]. Notably, carbo-RAPTA-C was significantly less effective in inhibiting cathepsin 
B than RAPTA-C, indicating that the release of leaving groups is required to exhibit 
inhibitory activity. Docking studies indicate that the ruthenium(II) ion binds to cysteine 
(Cys-29) in the catalytic pocket of the enzyme [119]. The adducts which form between 
RAPTA-T and apo-ZF-PARP retain both the arene and PTA ligands. The addition of 
RAPTA-T to the physiological ZF-motif (holo-ZF-PARP) resulted in the standard 
adduct types without loss of zinc ions, indicating that RAPTA-T coordinates to amino 
acids that are not involved in the structure of the zinc finger motif.  
 
5.2.3.2. Histone proteins as targets and target identification from cell extracts 
A significant percentage of RAPTA-C in cancer cells becomes associated with 
chromatin, ca. 5% in totаl, thus representing a key target [120]. Moreover, an X-ray 
structure of a nucleosome core particle (NCP - a double-stranded DNA segment which 
is wrapped around an octameric histone protein core) co-crystallized with RAPTA-C 
revealed binding to the histone core rather than DNA (Figure 29) [120]. A previous 
study of the interactions of a NCP and cisplatin or oxaliplatin revealed that both 
platinum complexes bound exclusively to DNA despite its lower accessibility in the 
particle [121]. It has also been shown that [Ru(η6-arene)(en)Cl]+ binds preferentially to 
DNA in the same model [81]. The study revealed three well-defined histone binding 
sites for RAPTA-C coordination with the dominate site corresponding to binding via 
two glutamate residues on the exposed, acidic face of the NCP. 
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Figure 29. The crystal structure of the nucleosome core particle (top) and a close-up of two of 
three RAPTA-C binding sites (bottom) (PDB ID: 3MNN) [120].  
 
While interactions with many different biomolecules may be anticipated for a relatively 
simple metallodrug in addition to the histone target described above, with the 
exception of histone proteins, interactions with the other biomolecules studied were 
not established in cellulo. In order to profile the molecular targets of RAPTA 
complexes, a drug pull-down approach based on drug affinity purification of cancer 
cell lysates with subsequent mass spectrometry and combined bioinformatics was 
applied [122]. The comparison of data sets obtained for cell lysates from cancer cells 
before and after pretreatment with a competitive binder suggested that the RAPTA 
complex interacts with a variety of intracellular proteins including several involved in 
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antiangiogenic and antimetastatic activity, such as pleiotrophin, midkine and, notably, 
histone proteins.   
Metallomics techniques have also been used to show the downstream effects on 
cancer cells in response to RAPTA-T treatment. Two-dimensional difference gel 
electrophoresis (2D-DIGE) was used to monitor changes in the expression of 
intracellular proteins upon exposure of cancer cells to RAPTA-T [123]. RAPTA-T 
changes the protein expression profiles of only a few proteins. DNA polymerase 
epsilon subunit 3 (POLE3), a histone-fold protein which interacts with other histone 
proteins to bind DNA, was profoundly downregulated, possibly as a direct 
consequence of RAPTA-binding to the histone core in chromatin. Several proteins 
were significantly upregulated including acetyl-CoA acetyltransferase, cytosolic 
(ACAT2), deoxyuridine 5´-triphosphate nucleotidohydrolase, mitochondrial (DUT), 
ubiquitin-conjugating enzyme E2 G1, omega-amidase (NIT2), thymidylate kinase 
(TMK), histidine triad nucleotide-binding protein 1 (HINT1) and prefoldin subunit 3 
(PFD3). Of these proteins the upregulation of HINT1 is particularly relevant since it is 
involved in the regulation of apoptotic processes and closely associated with p53 
expression. RAPTA-C was shown to induce p53 expression upregulation [124]. 
Multidimensional protein identification technology (MudPIT) was used to identify 
protein regulation in various organelles in cells treated with RAPTA-T [98]. Twenty-
five proteins demonstrated profound up- or down-regulation found in the endoplasmic 
reticulum, intermediate filament and mitochondria, nucleus and cytoskeleton. It is 
worth noting that most identified cytoskeletal proteins serve as constructive elements 
of cell junctions which might be partly responsible for the antimetastatic activity of 
RAPTA complexes, since the disruption of cell-cell interactions is related with 
metastasis [125, 126].   
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6. Concluding remarks 
Extensive studies on the anticancer properties of ruthenium(II) compounds have been 
reported, the main two classes comprising ruthenium(II)-polypyridyl complexes and 
organometallic ruthenium(II)-arene compounds [19-23, 111, 127, 128]. Of these 
various compounds the RAPTA-type compounds have been particularly well studied 
with several encouraging in vivo studies reported as well as detailed mechanistic 
studies. Indeed, the initial identification of RAPTA compounds provided an interesting 
contrast to the rest of this field – yielding prospective chemotherapeutics that exhibit 
activity against metastatic tumors and antiangiogenic effects that also leads to activity 
against primary tumors using appropriate dosing protocols whilst exhibiting low 
cytotoxicity in cell culture experiments. Such compounds highlight the potential of 
developing complementary metallotherapeutics that do not necessarily exhibit high 
cytotoxicity, but instead may be utilized with surgical intervention and complementary 
chemotherapeutic regimes in combination approaches. Such a strategy has potential 
in providing a more efficacious clinical outcome of the therapy regime accompanied 
by a reduction in side-effects. Since the discovery of the prototypical RAPTA 
compound, RAPTA-C, and the early recognition of its antimetastatic properties, the 
development of RAPTA compounds has rapidly progressed in the search for more 
efficacious compounds. This synthetic work has spanned the minor modification of 
individual ligands of the RAPTA structure to the construction of more targeted 
structures and complex macromolecular conjugates, and has resulted in a diverse 
range of compounds designed with a specific biological profile in mind. Alongside 
these synthetic achievements, efforts have been expended in the application and 
development of various bioanalytical, biochemical and biophysical techniques to 
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illuminate the mechanism by which RAPTA compounds exert their biological effects. 
The unique properties of RAPTA compounds, with respect to the observed 
biomolecular targets and biological effects, have led to the evaluation of RAPTA-C in 
several pre-clinical models. The activity of RAPTA-C on these models is highly 
promising, especially as it is coupled with its fast clearance from organs and the 
bloodstream and a low general toxicity. Remarkably, when administered during tumor 
normalization RAPTA-C is more effective in inhibiting tumor growth than the high 
cyctotoxic compound doxorubicin, even at a lower dose. Since RAPTA-C is 
reasonably water soluble and tolerates low pH it could potentially be administered 
orally and currently in vivo studies based on oral administration are in progress. 
Certain newer generation RAPTA-type compounds are also being studied in different 
pre-clinical models. 
Later RAPTA complexes, in particular those bearing fluorinated arene ligands and 
those bearing curcuminoid ligands, have shown particularly interesting properties, 
such as novel binding modes with biomolecular targets and high selective activity 
towards cancerous cell lines over non-cancerous cell lines, respectively. In addition, 
the development and evaluation of dinuclear RAPTA complexes is still in its infancy 
but these complexes display distinct crosslinking binding modes with biomolecular 
targets and can even be assembled in vitro. Rationally designed dinuclear complexes 
offer a route towards the crosslinking of targeted cellular components and the 
circumventing of cellular resistance mechanisms. Finally, the utility of macromolecular 
systems as RAPTA delivery vehicles has briefly been explored in cell-based studies. 
The continued development of synthetic routes and protocols for the incorporation of 
RAPTA compounds into well-defined macromolecular/supramolecular delivery and 
release systems is likely to provide a firm foundation for the future access of 
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conjugates able to favorably modify the pharmacological profile of these compounds 
in vivo.  
It is clear that for the protoypical RAPTA compounds there is little correlation between 
their in vivo activity and their activity in typical cell-proliferation studies. It is only when 
more targeted cell-based assays (e.g., those evaluating cell mobility, invasion and 
adhesion) were used in conjunction with appropriate cell lines that correlations could 
be drawn between in cellulo and in vivo activity. Given this paradigm, it is likely that 
there are examples of recently developed RAPTAs that warrant further evaluation in 
more appropriate assays and that a wider range of relevant pharmacoloigcal activity 
will be uncovered. As the application of proteomic techniques within this field becomes 
more routine it may be envisaged that the decision of which are the most appropriate 
cell-based assays in which to screen a compound will be led by results from 
proteomics studies. These results will indicate the essential targets in cellulo and from 
this the likely chemotherapeutic effects may be predictable. However, the progress 
made to date with the RAPTA compounds is extremely encouraging and the future 
combination of rational design with advanced proteomics should lead to the 
identification of more efficacious chemotherapeutics with promising anticancer 
properties. 
 
 
 
 
 
Table 1.  A summary of available in vitro and in vivo activity for all compounds discussed. 
# Structure Activity in vitro Activity in vivo Refs. 
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(IC50, 72 h, MTT 
assay unless 
stated 
otherwise) 
(1) 
Ru
Cl
Cl
P
N
N
N
 
TS/A: >300 μM 
HBL-100: >300 
μM 
 
A2780: 353±12 
μM  
CAM model (A2780 ovarian 
carcinoma):  inhibition of tumour 
growth by approx. 75% (0.2 mg kg-1 
per day for 5 days, starting 4 days 
after tumour inoculation). 
 
Athymic mice (LS174T colorectal 
adenocarcinoma):  50% inhibition 
of tumour growth (100 mg kg-1 per 
day for 11 days).  Antiangiogenic 
activity observed in tumour tissue. 
 
Athymic mice (LS174T colorectal 
adenocarcinoma):  Approx. 80% 
reduction in tumour growth when 
used in combination with erlotinib 
and BEZ-235 (single RAPTA-C dose 
of 40 mg kg-1). 
 
CAM model (A2780 ovarian 
carcinoma):  90% inhibition in 
tumour growth (400 μg kg-1) 
following pre-treatment with 
axitinib. 
[30] 
[37] 
[38] 
[39] 
[43] 
[45]   
(2) 
 
TS/A: >231 μM 
HBL-100: >300 
μM 
 [30] 
(3) 
 
TS/A: >74 μM 
HBL-100: >300 
μM 
 
MDA-MB-231: 
reduction in 
ability to 
adhere, 
migrate, detach 
and reduced 
invasive ability 
following 
treatment with 
RAPTA-T 
CBA mouse model (murine 
mammary carcinoma): reduction in 
weight of lung metastases and 
reduction in metastases of large 
dimensions (80 mg kg-1 per day on 
days 8,9,12 following implanting of 
tumour). 
[30] 
[36] 
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(4) 
 
TS/A: >66 μM 
HBL-100: >300 μM 
 [30] 
(5) 
 
TS/A: >300 μM 
HBL-100: >246 μM 
 [30] 
(6) 
 
TS/A: >110 μM 
HBL-100: >77 μM 
 [30] 
(7) 
 
TS/A: >199 μM 
HBL-100: >300 μM 
 [30] 
(8) 
 
TS/A: >159 μM 
HBL-100: >300 μM 
 [30] 
(9) 
 
TS/A: >103 μM 
HBL-100: >300 μM 
 [30] 
(10) 
 
TS/A: >570 μM 
HBL-100: >778 μM 
 [44] 
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(11) 
 
TS/A: >538 μM 
HBL-100: >715 μM 
 [44] 
(12) 
 
TS/A: >449 μM 
HBL-100: >603 μM 
 [44] 
(13) 
 
TS/A: >458 μM 
HBL-100: >813 μM 
 [44] 
(14) 
 
TS/A: >1000 μM 
HBL-100: >612 μM 
 [44] 
(15) 
 
TS/A: >820 μM 
HBL-100: >666 μM 
 [44] 
(16) 
 
TS/A: >1000 μM 
HBL-100: >1000 μM 
 [44] 
(17) 
 
TS/A: >505 μM 
HBL-100: >891 μM 
 [44] 
(18) 
 
A2780:  154-278 μM  [45] 
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(19) 
 
A2780: 507 μM 
 
 [46] 
(20) 
 
A2780: 38 μM   [46] 
(21) 
 
A2780: 78 μM  [46] 
(22) 
 
TS/A: >650 μM 
HBL-100: >738 μM 
 [48] 
(23) 
 
TS/A: >388 μM 
HBL-100: >1000 μM 
 [48] 
(24) 
 
(MTT assay, 48 h) 
MCF-7: 20 μM 
HT-29: 50 μM 
 
Inhibition of activity of GST P1-
1: IC50 = 13.7 μM 
 [49] 
[54] 
(25) 
 
Inhibition of activity of GST P1-
1: IC50 = 5.9 μM 
 [49] 
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(26) 
 
LN18, LN229, LNZ308, SW480, 
HT29, CaCo2, A549,  MDA-
MB231, MCF-7, HCEC, A2780, 
A280cisR: IC50 >200 μM in all 
cases for n = 1,2. 
 [52] 
(27) 
 
When X = COO, CONH:  
A549, A2780, A2780cisR, 
Me300, HeLa: IC50 >25 μM. 
 
When X = CH2O: A549, HeLa: 
IC50 >25 μM.  
A2780: IC50 = 19.7±6.5 μM. 
A2780cisR: IC50 = 15.8±6.0 μM. 
Me300: IC50 = 17.7±7.0 μM.   
 
When compounds 
encapsulated in [Ru6(η6-p-
cymene)6(tpt)2(donq)3]6+ cage 
IC50 values ranged between 
2.0 – 7.7 μM for all cell lines. 
 [53] 
(28) 
 
When n = 1 
A2780: IC50 8.5±1.4 μM.   
A2780cisR: IC50 6.9±1.5 μM. 
HEK: IC50 16.6±1.1 μM. 
 
When n = 2 
A2780: IC50 2.3±0.1 μM.   
A2780cisR: IC50 2.3±0.25 μM. 
HEK: IC50 6.6±0.2 μM. 
 
When n = 3 
A2780: IC50 6.5±0.5 μM.   
A2780cisR: IC50 9.1±1.7 μM. 
HEK: IC50 17.4±0.3 μM. 
 
 [56] 
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(29) 
 
When n = 1 
A2780: IC50 = 8.3±1.3 μM.   
A2780cisR: IC50 = 10±3 μM. 
MCF7: IC50 = 12±4 μM. 
 
When n = 2 
A2780: IC50 = 12±4 μM.   
A2780cisR: IC50 = 45±17 μM. 
MCF7: IC50 = 37±9 μM. 
 
 [58] 
(30) 
 
When * = R configuration 
A2780: IC50 = 44±1 μM. 
A2780cisR: IC50 = 396±3 μM. 
HEK: IC50 >1000 μM. 
 
When * = S configuration 
A2780: IC50 = 30±0.5 μM. 
A2780cisR: IC50 = 228±16 μM. 
HEK: IC50 = 255±13 μM. 
 
 
 [59] 
(31) 
 
When * = R configuration 
A2780: IC50 = 34±1 μM. 
A2780cisR: IC50 = 33±1 μM. 
HEK: IC50 = 32±1 μM. 
 
When * = S configuration 
A2780: IC50 = 8.7±0.1 μM. 
A2780cisR: IC50 = 21±2.5 μM. 
HEK: IC50 = 32±5 μM. 
 
 [59] 
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(32) 
 
Linker = ethylenediamine: 
A2780: IC50 = 64±9.5 μM. 
A2780cisR: IC50 >300 μM. 
HEK: IC50 = 35±5 μM. 
 
Linker = meso-1,2-
diphenylethylenediamine: 
A2780: IC50 = 20±0.5 μM. 
A2780cisR: IC50 = 95±6.5 μM. 
HEK: IC50 = 24±3.5 μM. 
 
Linker = (1S,2S)-(-)-1,2-
diphenylethylenediamine: 
A2780: IC50 = 3.7±0.6 μM. 
A2780cisR: IC50 = 4.5±0.2 μM. 
HEK: IC50 = 8.0±0.5 μM. 
 
 
Linker = (1R,2R)-(+)-1,2-
diphenylethylenediamine: 
A2780: IC50 = 3.7±0.6 μM. 
A2780cisR: IC50 = 7.0±0.5 μM. 
HEK: IC50 = 5.9±0.2 μM. 
 
IC50 values are complex 
concentrations. 
 [60] 
(33) 
 
Linker = ethylenediamine: 
A2780: IC50 = 23±0.5 μM. 
A2780cisR: IC50 = 88±10 μM. 
HEK: IC50 = 29±2.5 μM. 
 
Linker = meso-1,2-
diphenylethylenediamine: 
A2780: IC50 = 25±2.5 μM. 
A2780cisR: IC50 = 74±6.0 μM. 
HEK: IC50 = 19±4.0 μM. 
 
Linker = (1S,2S)-(-)-1,2-
diphenylethylenediamine: 
A2780: IC50 = 10±0.5 μM. 
A2780cisR: IC50 = 10±1 μM. 
HEK: IC50 = 6.0±1.0 μM. 
 
 
Linker = (1R,2R)-(+)-1,2-
diphenylethylenediamine: 
A2780: IC50 = 8.5±0.5 μM. 
A2780cisR: IC50 = 15±0.5 μM. 
HEK: IC50 = 6.0±0.5 μM. 
 
 [60] 
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IC50 values are complex 
concentrations. 
(34) 
 
A2780: IC50 >300 μM. 
A2780cisR: IC50 >300 μM. 
HEK: IC50 >300 μM. 
 [60] 
(35) 
 
A2780: IC50 >400 μM. 
A2780cisR: IC50 >400 μM. 
HEK: IC50 >400 μM. 
 [60] 
(36) 
 
A2780: IC50 = 12±1 μM.  [61] 
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(38) 
 
A2780: IC50 = 2.5±0.4 μM 
(preformed sample not 
isolated, IC50 given is complex 
concentration). 
 [61] 
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(39) 
 
A2780: IC50 = 288 μM 
 
When utilised to construct a 
rHSA-RAPTA conjugate IC50 = 
11 μM (rHSA concentration 
used, 3-4 RAPTA molecules 
per rHSA protein) 
 [63] 
(40) 
 
Utilised in labelling 
experiments with HEK cells. 
 [68] 
(42) 
 
(MTT assay, 96 h) 
CH1: IC50 = 26±1 μM. 
SW480: IC50 = 191±49 μM. 
A549: IC50 >640 μM. 
 
 [69] 
(43) 
 
A2780:  For dendrimers with 
4, 8, 16 or 32 RAPTA moieties 
the IC50 values when arene = 
p-cymene are IC50 = 174±40, 
9.3±0.4, 1.4±0.4, 0.8±0.1 μM 
respectively. 
When arene = 
hexamethylbenzene IC50 = 
8.9±2.8, 6.2±0.3, 2.9±0.1, 
2.0±0.1 μM respectively. 
 
A2780cisR:  For dendrimers 
with 4, 8, 16 or 32 RAPTA 
moieties the IC50 values when 
arene = p-cymene are IC50 = 
72.8±1.6, 19.3±0.2, 3.6±0.2, 
2.7±0.1 μM respectively. 
When arene = 
hexamethylbenzene IC50 = 
25±5.0, 11.8±1.1, 2.0±0.1, 
1.1±0.1 μM respectively. 
 
 [71] 
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(IC50 concentrations are 
dendrimer concentrations) 
(44) 
 
When arene = p-cymene 
A2780: IC50 = >200 μM 
A2780cisR: IC50 = 82.0±6.0 μM 
 
When arene = 
hexamethylbenzene 
A2780: IC50 = 38.0±3.4 μM 
A2780cisR: IC50 = 93.0±7.0 μM 
 [74] 
(45) 
 
Sulforhodamine B assay, 72 h. 
OVCAR-3 cell line. 
 
P(HPMA172-IEMA44-(RAPTA-C-
EMA)44) - IC50 concentration 
>IC50 for RAPTA-C at 
equivalent Ru concentrations. 
 [72] 
(46) 
 
WST-1 assay, 72h. 
Micelles formed from PLA347-
b-P(HEA74-(RAPTA-C-EMA)25) 
A2780: IC50 = 15 μM 
A2780cisR: IC50 = 24 μM 
OVCAR-3: 46 μM 
 
Micelles formed from PLA347-
b-P(HEA140-(RAPTA-C-EMA)45) 
A2780: IC50 = 51 μM 
A2780cisR: IC50 = 101 μM 
OVCAR-3: 61 μM 
 
 [73] 
(47) RAPTA-C covalently attached to [CP-
p(HEA58-co-CEMA10)2] that then self-
assembled into nanotubes. 
WST-1 assay, 72 h. 
A2780: IC50 = 15 μM 
A2780cisR: IC50 = 22 μM 
 
 [74] 
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(48) 
 
HT29: IC50 = 267 μM 
A549: IC50 = 1130 μM 
T47D: IC50 = 1174 μM 
MCF7: IC50 = >1600 μM 
 
 
 [75] 
(49) 
 
HT29: IC50 = 265 μM 
A549: IC50 = 1567 μM 
T47D: IC50 = 1088 μM 
MCF7: IC50 = >1600 μM 
 
 [78] 
(50) 
 
A549: IC50 = 51-97 μM except 
when R=Me, R’=H IC50 = >2000 
μM. 
A2780: IC50 = 7-15 μM. 
 
 [76] 
(51) 
 
CH1: IC50 = 8-46 μM. 
MG63: IC50 = 17-41 μM. 
HaCaT: IC50 = >100 μM except 
the 4-chlorophenyl-acac 
complex (72 μM). 
 [77] 
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(52) 
 
A2780: IC50 = 0.14-1.15 μM. 
A2780cisR: IC50 = 0.27-1.18 
μM. 
HEK293: IC50 = 4.5-30 μM 
 [78] 
(53) 
 
When R = Ph: 
A2780: IC50 = 18.9±0.8 μM. 
A2780cisR: IC50 = 19.5±0.3 μM. 
When R = Naph: 
A2780: IC50 = 6.0±0.5 μM. 
A2780cisR: IC50 = 6.1±0.5 μM. 
 
 
 [79] 
(54) 
 
Assessed as a RAPTA-based 
inhibitor of human hA1, hA2 
and hA3 adenosine receptors 
expressed in Chinese hamster 
ovary (CHO) cells. 
 [80] 
(55) 
 
Assessed as a RAPTA-based 
inhibitor of human hA1, hA2 
and hA3 adenosine receptors 
expressed in Chinese hamster 
ovary (CHO) cells. 
 [80] 
(56) 
 
TS/A: IC50 = >300 μM. 
HBL-100: IC50 = 37±3 μM. 
 
 [57] 
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(57) 
 
TS/A: IC50 = 124±13 μM. 
HBL-100: IC50 = 82±9 μM. 
 
 [57] 
(58) 
 
A2780: IC50 = 138 μM. 
 
 [82] 
(59) 
 
A2780: IC50 = 1.5 - 87 μM. 
A2780cisR: IC50 = 5 - 172 μM. 
 
 
 [83] 
(60) 
 
When PR3=PPh3  
A2780: IC50 = 184±12 μM. 
A2780cisR: IC50 = >200 μM. 
 
Otherwise: 
 
A2780: IC50 = 6 - 97 μM. 
A2780cisR: IC50 = 13 - >200 
μM. 
 
 
 [83] 
(61) 
 
A2780: IC50 = 43 - >300 μM. 
A2780cisR: IC50 = 34 - >300 
μM. 
 
 [86] 
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(62) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [86] 
(63) 
 
When R = H:  
TS/A: Reported as inactive. 
 
When R = Me: 
Antiproliferative effects 
observed starting at 10 μM 
(IC50 not specified) 
 [88] 
(64) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [89] 
(65) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [89] 
(66) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [89] 
(67) 
 
When R = Me 
A2780: IC50 = 5 μM. 
A2780cisR: IC50 = 6 μM. 
 
When R = Et 
A2780: IC50 = 4 μM. 
A2780cisR: IC50 = 10 μM. 
 
 [90] 
[90] 
(68) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [91] 
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(69) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [91] 
(70) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [91] 
(71) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [91] 
(72) 
 
Interaction with DNA probed.  
Cell-based cytotoxicity assays 
were not reported. 
 [91] 
(73) 
 
T2: IC50 = >50 μM. 
SKOV3: IC50 = >50 μM. 
 
 
 [92] 
(74) 
 
When R = Me 
T2: IC50 = >50 μM. 
SKOV3: IC50 = >50 μM. 
When R = CH2Ph 
T2: IC50 = >50 μM. 
SKOV3: IC50 = >50 μM. 
 
 [92] 
(75) 
 
When R = Me 
T2: IC50 = 50 μM. 
SKOV3: IC50 = >50 μM. 
When R = CH2Ph 
T2: IC50 = 2-10 μM. 
SKOV3: IC50 = >50 μM. 
 [92] 
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(76) 
 
T2: IC50 = 50 μM. 
SKOV3: IC50 = >50 μM. 
 
 [92] 
(77) 
 
Poor activity reported – no 
IC50 given. 
 [92] 
(78) 
 
Poor activity reported – no 
IC50 given. 
 [92] 
(79) 
 
When n = 12 
SKOV3: IC50 = 9.1±0.2 μM. 
SW480: IC50 = 9.7±0.15 μM. 
 
When n = 16 
SKOV3: IC50 = 9.6±0.2 μM. 
SW480: IC50 = 9.7±0.1 μM. 
 
When n = 18 
SKOV3: IC50 = 9.5±1.2 μM. 
SW480: IC50 = 9.1±1.3 μM. 
 
 
 [93] 
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(80) 
 
SKOV3: IC50 = 6.0±0.5 μM. 
A2780: IC50 = 4.7±1 μM. 
K562: IC50 = 5.1±0.3 μM. 
 
 [94] 
(81) 
 
SKOV3: IC50 = 8.3±0.8 μM. 
A2780: IC50 = 5.8±0.5 μM. 
K562: IC50 = 5.5±0.2 μM. 
 
 [94] 
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